The Emerging Role of Cyclin-Dependent Kinases (CDKs) in Pancreatic Ductal Adenocarcinoma

Baldina García-Reyes 1,†, Anna-Laura Kretz 1,†, Jan-Philipp Ruff 1, Silvia von Karstedt 2,3, Andreas Hillenbrand 1, Uwe Knippschild 1, Doris Henne-Bruns 1 and Johannes Lemke 1,*

1 Department of General and Visceral Surgery, Ulm University Hospital, Albert-Einstein-Allee 23, 89081 Ulm, Germany; balgarciareyes@gmail.com (B.G.-R.); annalaura.kretz@googlemail.com (A.-L.K.); jan-philipp.ruff@gmx.de (J.-P.R.); andreas.hillenbrand@uniklinik-ulm.de (A.H.); uwe.knippschild@uniklinik-ulm.de (U.K.); doris.henne-bruns@uniklinik-ulm.de (D.H.-B.)
2 Department of Translational Genomics, University Hospital Cologne, Weyertal 115b, 50931 Cologne, Germany; s.vonkarstedt@uni-koeln.de
3 Cologne Excellence Cluster on Cellular Stress Response in Aging-Associated Diseases (CECAD), University of Cologne, Joseph-Stelzmann-Straße 26, 50931 Cologne, Germany
* Correspondence: Johannes.lemke@uniklinik-ulm.de; Tel.: +49-731-500-53961
† These authors contributed equally to this work.

Received: 31 August 2018; Accepted: 11 October 2018; Published: 18 October 2018

Abstract: The family of cyclin-dependent kinases (CDKs) has critical functions in cell cycle regulation and controlling of transcriptional elongation. Moreover, dysregulated CDKs have been linked to cancer initiation and progression. Pharmacological CDK inhibition has recently emerged as a novel and promising approach in cancer therapy. This idea is of particular interest to combat pancreatic ductal adenocarcinoma (PDAC), a cancer entity with a dismal prognosis which is owed mainly to PDAC’s resistance to conventional therapies. Here, we review the current knowledge of CDK biology, its role in cancer and the therapeutic potential to target CDKs as a novel treatment strategy for PDAC.

Keywords: pancreatic cancer; pancreatic ductal adenocarcinoma; CDK; cyclin-dependent kinase

1. Background

Despite advances in diagnosis and therapy, carcinoma of the exocrine pancreas, especially pancreatic ductal adenocarcinoma (PDAC), imposes a grand challenge for oncology. PDAC is one out of only two cancers where there has been virtually no progress in survival rates over the last decades, the second one being lung cancer [1]. Because pancreatic cancer presents with non-specific symptoms, like diffuse abdominal discomfort and loss of appetite [2], it is often only diagnosed at a late stage, when it is more difficult to treat [3].

With an incidence of 4.2 per 100,000, pancreatic cancer is the 12th-most common cancer in humans [4]. Within malignancies of the gastrointestinal tract, PDAC ranks second behind the most commonly occurring colorectal cancer [1,5]. PDAC is one of the deadliest cancer entities, with a cumulative five-year-survival rate of only 8% [1,3]. This meagre survival is partly caused by late diagnosis as suggested by the fact that a solely localised tumour without metastases offers a four-times improved survival rate of 28% [1]. In cancer-associated mortality statistics, pancreatic cancer ranks fourth in both sexes [1]. It is a cancer entity associated with old age, as pancreatic cancer arises most frequently in the seventh and eighth decade, although, less frequently, it is also reported in people under 40 years of age [6].

The only potential cure for PDAC is surgical resection [2,7,8]. However, this possibility is hampered by the aggressiveness of this disease, presenting early spreading, invasion, distant metastases, and a typical resistance towards conventional radio- and chemotherapy [2,3,9–11]. At the time of diagnosis, only 15 to 20% of pancreatic cancers are operable (i.e., have not spread to other organs),
whereas the rest can only be treated through palliative chemotherapy, often with unfavourable results [12]. Most patients that have been treated with curative intent develop on-site relapse and distant metastases [2,13]. Therefore, clinicians are in need of adequate and effective chemotherapeutic regimens. Adjuvant treatments are mostly based on gemcitabine; palliative disease is mostly treated with gemcitabine or FOLFIRINOX (FOL = Folinic acid = Leucovorin, F = 5-FU = 5-Fluorouracil, IRIN = Irinotecan, OX = Oxaliplatin) or tyrosine-kinase inhibitor erlotinib [14,15].

The prodrug gemcitabine has been the gold standard for adjuvant treatment for a long time. However, the effects on improving median survival are only marginal at best [16,17]. Paclitaxel, nowadays prepared as nab-paclitaxel (nanoparticle albumin-bound), combined with gemcitabine improved therapeutic success, although not to a satisfactory level [18–20]. FOLFIRINOX has been a second line regime for advanced and metastatic pancreatic cancer since its introduction as PDAC treatment a few years ago [21,22]. However, new trends [23] indicate FOLFIRINOX as a first-line medicament in curative and adjuvant settings, as it was shown to be superior to gemcitabine, as it had a significantly better overall survival, disease-free survival, and metastasis-free survival during a randomized clinical trial [24,25].

Unfortunately, gemcitabine, nab-paclitaxel, and FOLFIRINOX are highly toxic [13,20,26,27]. In addition, currently approved therapies for PDAC yield unsatisfactory results. Hence, new therapeutic strategies with lowered toxicity and higher on-target efficacy are needed. Cyclin-dependent kinases (CDKs) have been proposed as possible targets of pharmacological inhibition for several cancer entities. Indeed, there are some successful examples of CDK inhibition in clinical settings, particularly against breast cancer, non-small-cell lung cancer, melanoma, and head and neck squamous cell carcinoma (reviewed in [28]). In the case of pancreatic cancer, the available clinical and pre-clinical evidence for a benefit in inhibiting CDKs is still scarce, although CDKs play an important role in the pathobiology of this disease.

2. Family of CDKs

Cyclin-dependent kinases (CDKs) are serine/threonine kinases that control cell cycle progression and other critical functions within the cell. Based on the homology of their catalytic domains, CDKs, along with the Mitogen-activated protein kinases (MAPKs), Glycogen synthase kinase-3β (Gsk3β), members of the dual-specificity tyrosine-regulated kinase (DYRK) family and CDK-like kinases belong to the CMGC group of kinases (named after the initials of its members) [29,30]. CDKs are activated by cyclins and act as a regulatory subunit. These CDK/cyclin complexes are fundamental to the orderly progression of the cell [31]. Studies examining the functions of CDKs and cyclins have uncovered that in fact, these proteins have other relevant roles besides regulation of the cell cycle [31,32]. These other roles include, for example, regulation of transcription, epigenetic regulation, metabolism, stem cell renewal, and spermatogenesis [33–36].

According to the classification of Malumbres et al. [37], there are 21 CDKs (see Table 1), sharing a conserved catalytic domain that comprises an ATP-binding pocket, the amino acid sequence PSTAIRE as a cyclin-binding domain and an activating T-loop motif. Active CDK/cyclin complexes depend on the phosphorylation of the T-loop on the respective CDK. Cyclins interact with the PSTAIRE helix, displacing the T-loop and exposing the substrate binding domain of the kinase thereby allowing for its phosphorylation. Unlike CDKs, cyclins are heterogeneous proteins, characterised by the presence of the so-called cyclin-box, which mediates binding to CDKs [38]. Outside this domain, their sequences are quite diverse. Most known cyclins promote CDK activity. There are several regulatory mechanisms for CDKs at the post-transcriptional level, CDK inhibitors exerting a negative regulation, phosphorylation status, protein folding, and subcellular localisation [39–41]. Phosphorylation can regulate CDKs in a negative and positive manner [42]. For example, CDK1 has inhibitory (threonine 14, T14; tyrosine 15, Y15 in CDK1) and stimulatory (threonine 161, T161 in CDK1) phosphorylation sites [43,44]. Phosphorylation at T14 and Y15 within the ATP-binding site by inhibitory kinases Wee1 and Myt1 interferes with proper ATP alignment, whereas T-loop phosphorylation at T161 by CDK-activating kinases (CAKs) improves substrate binding and complex stability to enable full CDK activation [42]. In this review, a summarized overview of the role of CDKs during cell cycle and transcription will be provided.
Table 1. Cyclin-Dependent Kinases with corresponding cyclins and their main function.

| CDK Subfamily * | Name ** | Other Names * | Cyclins | Main Functions | References |
|-----------------|---------|---------------|---------|---------------|-----------|
| CDK1            | CDK1    | CDC2, CDC28A, cell division cycle 2 homolog A, p34 protein kinase, p34 | Cyclin A, Cyclin B, Cyclin D, Cyclin E | Cell cycle—S phase, Cell cycle—G2/M phase | [45–48] |
| CDK2            | cell division protein kinase 2 | | Cyclin A, Cyclin B, Cyclin D, Cyclin E | Cell cycle—G1/S transition, Cell cycle—S phase | [49–52] |
| CDK3            | Cdkn3, Cell division protein kinase 3 | | Cyclin C, Cyclin E | Cell cycle—S phase | [53–55] |
| CDK4            | CDK4    | cell division protein kinase 4, CRK3, p34/cdk4, PSK-J3 | Cyclin D1, D2, D3 | Cell cycle—G1 phase, Cell cycle—G1/S transition | [56–58] |
| CDK5            | CDK5    | cell division protein kinase 5, CR6 protein kinase, CRK6, serine/threonine-protein kinase PSSALRE, tau protein kinase II catalytic subunit, TPKII catalytic subunit | p35 ***, Cyclin I | Development of the mammalian central nervous system, Apoptosis, Cell cycle regulation | [61–64] |
| CDK6            | CR2 protein kinase, CRK2, Serine/threonine-protein kinase PLSTIRE | | Cyclin D1, D2, D3 | Cell cycle—G1 phase, Cell cycle—G1/S transition | [56,59,60] |
| CDK7            | CDK7    | CAK1, CDKN7, STK1, 39 kDa protein kinase, CDK-activating kinase 1, cell division protein kinase 7, CRK4, protein-tyrosine kinase MPK-7, TFIIH basal transcription factor complex kinase subunit | Cyclin H | Transcription regulation | [65–67] |
| CDK8            | CDK8    | Cell division protein kinase 8, Mediator of RNA polymerase II transcription subunit CDK8 | Cyclin C | Transcription regulation, Wnt pathway modulation | [68–70] |
| CDK9            | CDK9    | CDC2L6, CDC2-related protein kinase 6, CDK11 | Cyclin C | Transcription regulation, Cell cycle | [70] |
| CDK10           | CDK10   | cell division protein kinase 10, PISSLRE | Cyclin K, Cyclin T1, T2a, T2b | Transcription regulation | [71,72] |

**Table 1.** Cyclin-Dependent Kinases with corresponding cyclins and their main function.
| CRK7 CDK12 | CDC2 related protein kinase 7, cell division cycle 2-related protein kinase 7, CRK7, CRKR | Cyclin K, Cyclin L | Transcription regulation Splicing | [74,75] |
|---|---|---|---|---|
| CRK7 CDK13 | CDC2L, CDC2L5, CDC2-related protein kinase 5, cell division cycle 2-like 5, cell division protein kinase 13 | Cyclin K | Transcription regulation Splicing | [74,76] |
| PITSLRE CDK11A | CDC2L2, CDC2L3, CDK11-p110, CDK11-p46, CDK11-p58, cell division cycle 2-like 2 (PITSLRE proteins), Cell division cycle 2-like protein kinase 2, Cell division protein kinase 11A, PITSLRE serine/threonine-protein kinase CDC2L2 | Cyclin L1, L2 | Splicing | [77,78] |
| PITSLRE CDK11B | CDC2L1, CDK11-p110, CDK11-p46, CDK11-p58, cell division cycle 2-like protein kinase 1, cell division protein kinase 11, PITSLRE serine/threonine-protein kinase CDC2L1, PITSLRE serine/threonine-protein kinase CDC2L1CDK11-p110 | Cyclin L1, L2 | Splicing | [77,78] |
| TAIRE CDK14 | cell division protein kinase 14, PFTAIRE protein kinase 1, PFTAIRE1, PFTK1 | Cyclin D, Cyclin Y | Cell cycle progression Wnt signaling | [79,80] |
| TAIRE CDK15 | ALS2CR7, PFTAIRE protein kinase 2, PFTAIRE2, Cell division protein kinase 15, frizzled family receptor 7 | Cyclin Y | Associated with TRAIL resistance in cancer cells | [81] |
| TAIRE CDK16 | cell division protein kinase 16, CRK5, PCTAIRE protein kinase 1, PCTAIRE1 | Cyclin Y | Neurite outgrowth regulation Vesicle trafficking Cancer cell proliferation | [82] |
| TAIRE CDK17 | PCTAIRE protein kinase 2, PCTAIRE2 | Cyclin Y | Expressed in brain | [83,84] |
| TAIRE CDK18 | cell division protein kinase 18, PCTAIRE protein kinase 3, PCTAIRE3 | Cyclin A2, Cyclin E | Actin reorganization regulation Genome integrity regulation | [85–87] |
| CCRK CDK20 | CCRK, CDK-related protein kinase PNQLARE, cell division protein kinase 20, Cyclin-dependent protein kinase H, Cyclin-kinase-activating kinase p42 | Cyclin E | Cell cycle regulation | [88,89] |

* according to the classification of Alexander et al. 2017 [90]; ** according to the classification of Malumbres et al. 2009 [37]; *** p35 is not classified in the cyclin family, although p35 and cyclins present a similar three-dimensional conformation that can interact with CDKs [91,92].
3. Cell Cycle Regulation by CDKs

The cell cycle is one of the most essential and evolutionarily conserved cellular processes. CDKs and cyclins are the main proteins responsible for driving it [93–95]. Typically, these protein families act as heterodimers regulating different steps of the cell cycle, as CDK/cyclin complexes (Figure 1). CDKs unbound to cyclins are usually inactive, but upon the formation of a complex with a cyclin partner, they become able to phosphorylate different targets, resulting in target inactivation or repression. CDKs are constitutively expressed in the cell while cyclin expression is highly dependent on the stage of the cell cycle, hence their name. This fluctuating expression pattern of cyclins constitutes a mechanism by which the orderly progression of the cell cycle is regulated.

![Figure 1. The cell cycle phases and their associated cyclin-dependent kinases (CDK)/cyclin complexes.](image-url)

In the G1 phase of the cell cycle, the synthesis of cyclin D is increased. This cyclin partners with CDK4/6 to promote cell cycle entry, and its progression through G1, as well as the G1/S transition. During the S phase, CDK2 in complex with cyclin A controls the phosphorylation of targets involved in DNA replication. Cyclin A is found highly expressed in this phase and until the last stages of G2. In the G2 phase, the primary regulator of the cell cycle is CDK1.

In the G1 phase of the cell cycle, the synthesis of cyclin D is stimulated. This cyclin is a partner of CDKs 4 and 6 [96]. Complexes of these CDKs and cyclin D promote cell cycle entry, progression through G1, and G1/S transition [56,97]. Cyclin D regulation is complex, depending mainly on the RAS/RAF/MEK/ERK signalling pathway for its transcription [98,99]. It is also regulated by its constant rate of degradation through the proteasome, mediated by GSK3β [100]. GSK3β phosphorylates cyclin D1, which primes it for its subsequent ubiquitination. The primary cell cycle-related target of the CDK4/6-cyclin D complex is the Retinoblastoma protein (Rb). Rb is one of the main repressors of the G1 to S phase transition [101], through its inhibitory activity on E2F, a transcription factor that promotes the expression of genes required for DNA synthesis and mitosis [102]. In humans, Rb contains 16 known phosphorylation sites that are targeted by CDKs [103,104], and its phosphorylation status varies along the cell cycle [105]. In its hypophosphorylated form, Rb can form a complex with E2F and repress its activity. Besides CDK4/cyclin D and CDK6/cyclin D, two other related complexes are known for their ability to hyperphosphorylate Rb: CDK2/cyclin E during G1, and CDK2/cyclin A during S phase [106].
One of the transcriptional targets of E2F is CCNE1 encoding cyclin E [107], which in turn represses Rb when in a heterodimer with CDK2 [56]. CDK2/Cyclin E complexes act mainly in the G1 and S phases of the cell cycle [96], however, its levels are reduced after the early stages of the S phase by proteasomal degradation. This particular complex has a broader range of targets related to the cell cycle, such as DNA replication and centrosome duplication [108]. CDK2 in complex with cyclins A1 or A2 is associated with S phase, with A2 being ubiquitously expressed in mice germ cells [109]. During this phase, cyclin A partners with CDK2 to phosphorylate targets involved in DNA replication [110]. Cyclin A is found highly expressed in this phase and until the last stages of G2. At the G1/S checkpoint, the cell halts its progression in the cell cycle if the conditions are not favourable for division. This checkpoint is partly controlled by the inhibition of the CDK4/cyclin D complex by the Inhibitor of CDK4 (INK4) family. These inhibitors competitively bind to CDK4 and CDK6, preventing, in turn, their binding to cyclin D, which is then degraded [100]. Either growth-induced or oncogene-induced overexpression of cyclin D alters this dynamic and pushes the cell towards the S phase [111].

In G2 phase, after the cell has duplicated its DNA during S phase, the primary regulator of the cell cycle is the complex formed between CDK1 and cyclin B. So far, more than 70 proteins have been identified as cellular targets of phosphorylation mediated by this complex [94], influencing many cell cycle-critical events, such as the separation of centrosomes [112], the condensation of chromosomes [113], breakdown of the nuclear lamina [114], and disassembly of the Golgi apparatus [115]. The activation of the CDK1/cyclin B complex is inhibited when DNA damage of genotoxic stress is present [116]. Also, its subcellular localisation is a regulation mechanism. CDK1 can be sequestered in the cytoplasm by the protein 14-3-3σ when it is separated from its partner cyclin B, either by competitive binding with p21Cip1 or directly dissociated by the Growth Arrest and DNA Damage-inducible GADD45 [117].

This complex network of CDK/cyclin interactions is not fully understood, not only because many other functions of these proteins have emerged in recent years, but also because there are many instances of functional redundancy in the cell cycle. For example, in the absence of CDK4/6, CDK2 can take over their functions when in complex with cyclin D [36]. In a similar manner, CDK1 can substitute for CDK2 and 4. In fact, the only essential CDK in the cell cycle is CDK1 which cannot be substituted for by another CDK [48]. In the absence of CDK2, CDK3, CDK4, and CDK6 in mouse embryos, CDK1 was able to bind to all cyclins, leading to the phosphorylation of Rb, an event required for cell cycle progression. However, the embryos were unable to develop past the morula and blastocyst stages in the absence of CDK1, showing that this CDK can drive cell division by itself [48].

4. Transcriptional Regulation by CDKs

Transcription is a process that can be influenced at several levels by CDKs, such as with their influence on E2F, [105,118] and the transcription factor FoxM1 during G2 phase by CDK2/cyclin A and CDK1/cyclin B [119–122]. Also, CDKs are also able to influence the transcription process more directly through regulation of RNA polymerase II (RNA Pol II)-dependent transcription (Figure 2). CDKs can both negatively and positively influence the functionality of RNA Pol II. CDK8 and CDK19 are components of the Mediator complex as part of a 4-subunit subcomplex with cyclin C, Mediator complex subunits MED12 and MED13. This complex acts as an inhibitor of RNA Pol II by phosphorylating its C-terminal domain (CTD), a process which blocks RNA Pol II participation in the pre-initiation complex that drives transcription in eukaryotes [123–125]. In contrast to this, there is also CDK-mediated phosphorylation of the RNA Pol II CTD at distinct sites leading to positive regulation of RNA Pol II activity. The pre-initiation complex includes CDK7, its partner cyclin H, and MAT1 (Menage à Trois 1) as a catalytic subunit (named TFIIH) that phosphorylates the CTD of RNA Pol II. This phosphorylation allows for initiation of transcription and elongation to happen [126]. TFIIH, in turn, can also be negatively regulated by CDK8-mediated phosphorylation of cyclin H.
CDK9 promotes phosphorylation of RNA Pol II as a subunit of the positive transcription elongation factor b (pTEFb), where it is found bound to cyclin T1. It also phosphorylates the negative elongation factor NELF, allowing for the extension of the nascent pre-mRNA [127,128]. A mouse study indicates that CDK9 is essential for development and embryonic genome activation. Inhibition of the kinase activity of positive transcription elongation factor b (pTEFb) using the CDK9-specific inhibitor, flavopiridol, caused defects in transcription, abnormal localisation of pTEFb, and developmental arrest in mouse two-cell stage embryos [129]. pTEFb is required for transcription of most genes [130], which explains the drastic consequences observed in this study.

Other CDKs involved in the transcription process are CDK11, 12, and 13. CDK11 has been found to co-immunoprecipitate with the elongation factors ELL2, TFIIE, TFIIJ, and FACT, as well as with RNA Pol II itself [31]. Moreover, CDK11 is thought to phosphorylate RNA Pol II on its CTD [131]. CDK12 and CDK13 are also able to phosphorylate RNA Pol II, when in complex with cyclin K [132,133].

Another fundamental process via which CDKs influence transcription is the canonical Wnt pathway. CDK8 kinase activity has been found to be necessary for β-catenin-driven transformation and expression of several β-catenin transcriptional targets [69], while CDK14/cyclin Y complexes are responsible for the phosphorylation of Lrp6, a Wnt coreceptor. This phosphorylation primes Lrp6 for its phosphorylation by the membrane-bound Casein Kinase 1 gamma, leading to the binding of Axin, which is then unable to form part of the destruction complex that ubiquitinylates β-catenin. This chain of events leads to increased TCF/LEF mediated transcription [31].

As such, the examples mentioned above illustrate the diverse roles CDKs play in major cellular processes, and it is likely that more roles of this family will be discovered. It is clear that although their role in the cell cycle has been extensively studied, more research is needed to fully understand CDKs’ integral role in the cell and other central processes in cell biology.

5. The Role of CDKs in Pancreatic Cancer

The dysregulation of CDK and cyclin activity in the cell cycle is often found elevated in human tumours and is associated with the unrestrained proliferation of cells, an essential hallmark of
To maintain these malignant rates at which cells cycle, cancer cells acquire additional mutations which help to circumvent cell cycle checkpoints that usually safeguard genomic integrity and control proliferation [135,136]. A plethora of aberrant CDK behaviour has been described for various tumour entities [44,134,137–139]. However, in this review, we will focus on CDK dysregulation described for pancreatic cancer.

Signal transduction cascades activated by proto-oncogene \textit{KRAS}, \textit{CDKN2A} (encoding the tumour suppressors p16INK4a and p14ARF) and \textit{TP53} intersect on the cell cycle, thereby promoting the transition from G0 or G1 phase into S phase [140]. Since pancreatic cancers carry activating mutations in \textit{KRAS}, loss-of-function mutations in \textit{TP53}, and \textit{CDKN2A} in >90%, 50%, and 80% of tumours respectively, controlling CDKs might significantly impact PDAC [3,141–143]. So far, histopathological investigations of pancreatic cancer tissue have identified intraepithelial neoplasia (PanIN) lesions which illustrate the multistep genetic progression leading to invasive PDAC. Early stages include the activation of \textit{KRAS} with subsequent inactivation of \textit{TP53} and \textit{CDKN2A/2B} in advanced stages [143].

A crucial checkpoint, controlled by the CDK4/6-cyclin D-Rb pathway, is the transition from G1 to S phase [144]. Consequently, dysregulation of the Rb pathway results in enhanced proliferation [145–148]. Against the background of a high frequency of \textit{KRAS} mutations, which is the case in PDAC, the CDK4/6 inhibitor encoding function of the \textit{CDKN2A} locus is principally relevant [26]. Despite its oncogenic function, if mutated \textit{KRAS} is expressed in cells with intact cell cycle checkpoints, it triggers a senescent-like state referred to oncogene-induced senescence leading to cell cycle arrest in G1 phase thereby preventing further transformation of the tissue [149–152]. Oncogene-induced senescence is triggered by either p53 or p16INK4a encoded by \textit{CDKN2A} that inhibits CDK4/CDK6 and prevents the catalytic activity of the CDK/cyclin D complexes [153–157]. CDK4/6-cyclin D-associated hyperphosphorylation of Rb is prevented and consequently S-phase entry through suppression of E2F-mediated transcription [154,158]. In fully developed PDAC, oncogene-induced senescence is bypassed through inactivating of either Rb and/or \textit{TP53} or mutation of p16INK4a [158]. In line with this, germ-line mutations of p16INK4a have been associated with an elevated risk for developing PDAC through uncontrolled CDK4/6-mediated proliferation [149,159]. Besides, recent data underpin a concerted action of mutant \textit{KRAS} with CDK5 and its activators to intensify malignant progression, migration, and invasion of pancreatic cancer cells [160]. CDK5 holds a unique position within the CDK family, as it becomes activated by the non-cyclin proteins p35 and p39. Although CDK5 shares high homology with CDK2, it has a marginal role in cell cycle control. Most substrates of CDK5 are associated with cell morphology and motility as well as cell–cell communication [161]. Different studies support the relationship between \textit{KRAS} altered status and CDK inhibition as a potential avenue of treatment in cancer. CDK8 expression was found increased in \textit{KRAS}-mutated pancreatic cancer samples [162], while \textit{KRAS}-mutated PDAC was shown to be sensitive to CDK9-inhibition in patient-derived xenografts [163], and downstream inhibition of \textit{KRAS} via AKT-inhibition combined with CDK-inhibition via dinaciclib showed dramatic improvements—even complete responses—in patient-derived xenograft models of pancreatic cancer in mice [164]. Of note, CDK4 inhibition was shown to be synthetically lethal with \textit{KRAS} mutations in non-small cell lung cancer (NSCLC), an observation yet to be explored for PDAC [165].

Interestingly, pancreatic acinar cells of adult mice have been found to be resistant to transformation by \textit{KRAS} with or without loss of p16Ink4a/p19Arf or \textit{TP53}, yet they will show PanIN and even PDAC if mice were experimentally induced to develop pancreatitis. If expression of oncogenic \textit{KRAS} was induced after pancreatitis induction, this would only induce PDAC in mice if residual inflammation was still present [166]. In this case, it is thought that the inflammatory response reduces the occurrence of senescence observed in benign lesions. Importantly, it has been found that the CDK4/6 inhibitor palbociclib is able to induce senescence in a breast cancer cell line [167], highlighting CDK inhibition as an interesting avenue of research in senescence induction and its role against oncogenic transformation.

DNA lesions caused by destructive reagents such as chemotherapeutics may trigger checkpoint arrest in the cell cycle and block CDK activity [168–173]. DNA damage regularly initiates the p53/p21
pathway resulting in G1 arrest to allow the repair machinery to restore genome stability. There is plenty of evidence in mice and human cells showing the p53-induced regulation of CDK2 by the inhibitor protein p21 [168,173]. Interestingly, it was also shown that apart from that checkpoint element, the binding of CDK2/cyclin E complexes, p21 binds CDK4/cyclin D and suppresses their kinase activities in a p53-dependent manner [174]. Since a vast number of pancreatic tumours carry silencing mutations of TP53, this checkpoint is also eliminated.

In case of overexpressed p16, the cellular response is either cell cycle arrest or apoptosis in different pancreatic cancer cell lines [175]. While p16 inhibits CDK4/6 activity leading to growth arrest, p16-induced apoptosis requires activation of p53-dependent cell death pathways [176–178]. In line with these findings, earlier results indicated the disruption of CDK4/6 by p16 leading to the rearrangement of the CDK inhibitors p21Cip1 and p27Kip1 [39]. p21/p27 are involved in binding and activity of CDK4/6-cyclin D enzymes, while they are also potent inhibitors of CDK2. p27 loss is frequently associated with tumorigenesis and it has been found that KRAS activation in the pancreas is associated with p27 mislocalization, while the absence of p27 or its ability to bind CDKs triggers the mislocalization of acinar polarity markers related to metaplasia and induces the nuclear expression of transcription factors involved in acinar-to-ductal metaplasia [179]. Also, it was shown that cyclin E overexpression facilitates p16-mediated circumvention of G1 arrest [180,181]. The molecular mechanism of the various fate of pancreatic cancer cells upon CDK4/6 inactivation is associated with the modulation of CDK2 activity [175].

CDK1 monitors M phase entry and exit and binds either cyclin A or cyclin B [134]. In addition to G2/M checkpoint maintenance, the activation of CDK1 is essential to governing mitosis, execution of apoptosis, pluripotency, and genomic stability in human pluripotent stem cells, their proliferation comparable to those of cancer cells [182]. Inactive CDK1, induced for example by cyclin damage, is a condition leading to a shift from M phase and the reconstruction of the G1 phase [183,184]. However, CDK1 activity was identified as essential for tumorigenesis as cell proliferation in transformed cells is mediated by CDK1 [184]. Tumour cells have some proliferation characteristics in common with stem cells; nevertheless, they appear more sensitive to loss of CDK activity [185]. The downregulation of CDK1 in human embryonic stem cells (hESC) and human induced pluripotent stem cells (hiPSC) leads to cell cycle modifications arresting the cells in G2 phase at the expense of G1 and S phase. In both cell types, the loss of the pluripotent stem cell morphology could be detected upon CDK1 downregulation. Knockdown of CDK1 resulted in a significant rise of double-strand breaks [182]. The growth of pancreatic cancer cell lines was reduced when CDC25B, an activator of CDK1, was inhibited resulting in accumulation of phosphorylated CDK1 and G2/M arrest [186].

In addition to their cell cycle-regulating features, a subset of CDKs, most importantly CDK7 and CDK9, have been identified to regulate RNA Pol II-mediated transcription [187,188]. We could recently demonstrate that the upregulation of CDK9 in human pancreatic cancer tissue negatively correlated with patients’ survival. These results became even more significant when the cohort was subdivided by tumour grades revealing a strong correlation between high CDK9 expression levels and reduced overall survival of PDAC patients with well-differentiated tumours (grade 1, grade 2) [139].

6. CDK Inhibition in PDAC

Due to their central role in cell cycle control, it is hardly surprising that CDKs and their substrates and regulators are identified as targets of genetic manipulations in various human cancers, which has accelerated the development of small molecule inhibitors against CDKs as an anticancer approach [26,189,190]. The “standard of care” for pancreatic cancer, which means the best treatment known so far, is still disappointing regarding the median overall survival of only six months [17,20,191]. Thus, there is a growing demand for new, more effective treatment possibilities, going in the direction of targeted therapies [26,190]. Of note, unfavourable toxicity profiles and severe adverse effects limited clinical success of potential CDK inhibitor candidates which is thought to be caused by inhibitory activity towards CDK1 which is known to be essential for all living cells [190].
Since the loss of p16INK4a is a standard feature in KRAS-driven PDAC [143], specific pharmacological inhibition of CDK4/6 is of substantial interest and presents a possible target for treatment. So far it has not been possible to design an inhibitor that is completely selective for a specific CDK, due to the lack of three-dimensional structure-displaying models of various CDKs and the high homology within the CDK family.

Currently, the oral CDK4/6-specific compounds palbociclib (PD-0332991) [192], ribociclib (LEE-011) [193], and abemaciclib (LY2835219) [194] are approved for the treatment of breast cancer. They inhibit retinoblastoma (Rb) protein phosphorylation in early G1 phase. Inhibition of Rb phosphorylation, in turn, avoids CDK-mediated G1-S phase transition, thereby arresting the cells in the G1 phase, suppressing DNA synthesis and constraining cancer cell growth. Notably, the approach is likely to fail in cells exhibiting intact Rb, whereas palbociclib has been demonstrated failing in Rb-negative cancers [192]. Loss-of-function mutations in p16(INK4A) (CDKN2A) and therefore in the Rb pathway is a common feature of PDAC, and cause of an early progression in the disease. While this silencing activates CDK4/6, p16(INK4A)-deficient PDAC is nonetheless widely resistant to pharmacological CDK4/6 inhibition [195]. Furthermore, Chou and collaborators showed that inhibition of CDK4 with palbociclib significantly induces apoptosis in pancreatic tumour overexpressing Rb and also enhances the apoptotic effect of chemotherapeutic gemcitabine in patient-derived xenografts in mice. These studies suggest that a combination therapy including CDK4/6 inhibitors could be beneficial in Rb-positive pancreatic tumours and Rb can be used as a tool to select the patients that would benefit the most from this strategy. The approach of CDK4/6 inhibition by palbociclib was also evaluated in combination with IGF1 receptor inhibitors [196] and patient-derived models of pancreatic cancer primary tumour explants. The targeted therapy combinations exhibited robust cytotoxicity towards tumour cells [196]. The CDK4/6 inhibition resulted in potent suppression of tumour growth in the primary tumour explants illustrating the similarities of the biology between primary tumour model and tumour of origin [192]. LY2835219 inhibits CDK4/6 leading to reduced tumour growth in human xenografts, however, not demonstrated up until now for pancreatic cancer. The effect was enhanced in an epithelial tumour xenograft when the inhibitor was administered in combination with gemcitabine [194].

Although the underlying mechanism needs to be clarified, metabolic functions organise cell division [197] as the execution of the cell cycle entry is accompanied by an increase in cellular mass and accretion of energetic metabolites necessary for cell division [198]. However, much of the metabolic network is driven by mutated KRAS in a concerted manner with tumorigenic proliferation [199,200]. As metabolic characteristics of cancer gradually evolve as a therapeutic target, the CDK4/6 inhibitor-mediated metabolic state might be considered as a therapeutic target [201]. During the cell cycle, CDK4/6 inhibition has different effects but leads to the increase of tumour-associated mitochondrial mass via Rb and reactive oxygen species (ROS). Oxidative and glycolytic metabolic pathways are stimulated upon CDK4/6 inhibition. Apart from that, mTOR signalling is activated as a consequence of CDK4/6 blockade in vivo. These results indicate an active, feed-forward loop involving mTOR pathways for metabolic reprogramming. Consequently, cooperating effects could be shown with mTOR inhibitors resulting in apoptosis induction [201]. The fact that treatment alone with CDK4/6 inhibitors seems not very promising for pancreatic cancer [26], the CDK4/6 inhibition-mediated metabolic state might be additionally targeted [202]. Alternatively, the activity of CDK4/6 inhibitors can be exploited by the combination with mTOR pathway-selective compounds [203]. To overcome the robust apoptotic resistance of pancreatic cancer cells [9], the targeting of the tumour necrosis factor-related, apoptosis-inducing ligand receptors (TRAIL-R1/2) by their ligand TRAIL, in combination with CDK4/6 inhibitors could be used as an anticancer strategy. Indeed, blockade of CDK4/6 sensitises PDAC cells towards TRAIL-induced apoptosis [204]. However, there is additional need for optimisation of these treatment strategies since CDK4/6 inhibition antagonises chemotherapy and radiotherapy as their efficacy mostly relies on the fact that cancer cells undergo fast and uninhibited cell divisions [205,206].
Conversely, there is evidence that release from CDK4/6 inhibition may synchronise cells to go through the cell cycle in a concerted manner and eventually sensitise them to subsequent chemotherapy or may avoid current proliferation or repopulation of cells between treatment cycles [97]. P276-00, a CDK1, CDK4, and CDK9 inhibitor, could sensitisise pancreatic cancer cells to gemcitabine-induced apoptosis. The data indicate that the combination might simultaneously target CDKs and Akt/mTOR signalling to inhibit both tumour progress and angiogenesis [207]. Angiogenesis is further influenced by CDK8, which has been found that when overexpressed, it promotes angiogenesis in pancreatic cancer via activation of CDK8/β-catenin/KLF2 signalling, while silencing of CDK8 inhibits angiogenesis in pancreatic cancer in vitro and in nude mice xenograft models [208]. However, the transfer of these hopeful preclinical models to the clinic, where vast genetic tumour heterogeneity and, consequently, dynamics of tumour growth are highly inconsistent between patients, is extremely challenging [209,210].

Dinaciclib (SCH727965) is a small molecule inhibitor with on-target activity in the low nanomolar range against CDK1, CDK2, CDK5, and CDK9. Pre-clinical testing of the substance showed acceptable toxicity and promising efficacy in mouse models and was well tolerated and active in phase I clinical trials [211,212]. Therefore, dinaciclib entered phase III clinical trials with refractory chronic lymphocytic leukaemia (CLL) [213]. In preclinical models for PDAC, monotherapy with dinaciclib inhibited growth, migration, and colony formation of pancreatic cancer cells through the blockage of cell cycle progression and reduction in Rb phosphorylation. Furthermore, this inhibition reduces RaLa activity [214]. RaLa is an effector of RAS signalling and plays a critical role in tumorigenicity of PDAC, observed for both human and mice [215–217]. RaLa can be blocked by inactivation of CDK5 probably through effector cascades downstream of oncogenic KRAS. In PDAC xenografts the effects could be verified shown by a significant reduction in tumour growth [214].

Indeed, it has been demonstrated that CDK9 facilitates resistance to apoptosis through the transcriptional control of anti-apoptotic proteins such as Mcl-1 [218]. SNS-032 is a CDK9-selective inhibitor already undergoing clinical testing [219–221]. CDK9 was shown to be overexpressed in PDAC tissue and the in vitro response of pancreatic cancer cell lines results in markedly reduced cell viability upon CDK9 inhibition [139]. CDK9 inhibition by SNS-032 might, therefore, pose a promising therapeutic approach for pancreatic cancer. Mechanistically, CDK9 inhibition leads to apoptosis induction by shifting the ratio of anti-apoptotic and pro-apoptotic proteins in line with previous reports describing the inhibition of transcriptional elongation as an antagonist of short-lived anti-apoptotic proteins. As additive effects of CDK inhibition could be achieved in combination with chemotherapeutics, it might be promising to explore this approach as an alternative to conventional treatment strategies [188].

Rohitukine, a plant-derived chromone alkaloid, is the precursor of the promising anticancer clinical candidates flavopiridol (also known as alvocidib, HMR 1275, L86-8275) [222–224] and P276-00 [223,225]. However, the antitumor activity, pharmacokinetics, and CDK inhibitory potential of this parental product were not studied in detail for a long time. Eventually, in vitro toxicity could be reported in a variety of cancer cell lines including pancreatic cancer by the inhibition of CDK2 and CDK9 [226]. With the knowledge of the physicochemical properties and targets, the scaffold of rohitukine might be used for the design of further derivates.

7. Clinical Trials of CDK-Inhibitors

As discussed above, CDK-inhibition could be a promising strategy for new, advanced therapy protocols to treat pancreatic cancer. There are several ongoing clinical trials with a high number of CDK-inhibitors which we have summarized in Table 2. Unfortunately, pancreatic cancer as an entity is vastly underrepresented in these studies, with only a few results obtained so far.
Table 2. CDK-specific inhibitors currently studied in clinical trials.

| Drug       | Targeted CDKs | Clinical Trial Phase | Disease                                                                 | Observations                                                                 |
|------------|---------------|----------------------|--------------------------------------------------------------------------|------------------------------------------------------------------------------|
| Flavopiridol | 1, 2, 4, 6, 7, 9 [26] | Phase I              | Chronic Lymphocytic Leukemia (CLL) [27]                                  | After chemoimmunotherapy                                                    |
|            |               |                      | Advanced solid tumours [227]                                             | In combination with oxaliplatin and fluorouracil/leucovorin                  |
|            |               |                      | Advanced solid tumours [228]                                             | In combination with FOLFI RI                                                |
|            |               |                      | Advanced solid tumours [229]                                             | In combination with docetaxel                                               |
|            |               |                      | Advanced sarcomas [230]                                                  | In combination with doxorubicin                                             |
|            |               |                      | Pancreatic cancer [231]                                                  | In combination with radiation and gemcitabine                               |
|            |               | Phase II             | Metastatic melanoma, endometrial adenocarcinoma, multiple myeloma [190] |                                |
|            |               |                      | Pancreatic cancer [232,233]                                              | In combination with docetaxel                                               |
| Dinaciclib  | 1, 2, 5, 9 [211] | Phase I              | CLL [234]                                                                |                                |
|            |               |                      | Advanced malignancies [212]                                               |                                |
|            |               |                      | Triple-negative breast cancer [235]                                       | In combination with epirubicin                                              |
|            |               |                      | Pancreatic cancer [236]                                                  | No results published yet                                                   |
|            |               | Phase II             | Multiple myeloma [237]                                                   |                                |
|            |               |                      | Advanced breast cancer [238]                                             | In comparison vs. capecitabine                                              |
|            |               |                      | Non-small cell lung cancer (NSCLC) [239]                                 | In comparison vs. erlotinib                                                |
|            |               | Phase III            | CLL [213]                                                                |                                |
|            |               |                      | Metastatic refractory solid tumours [220]                                | In comparison vs. ofatumumab                                               |
|            |               |                      | CLL, multiple myeloma [221]                                              |                                |
| SNS-032    | 2, 7, 9 [219]  | Phase I              | Metastatic refractory solid tumours [220]                                |                                |
| Abemaciclib | 4, 6 [240]    | Phase II             | Pancreatic cancer [241]                                                  | In combination with gemcitabine, capecitabine                              |
|            |               |                      | Advanced breast cancer [242] (MONARCH 1)                                 |                                |
|            |               | Phase III            | Advanced breast cancer [243] (MONARCH 2)                                 | In combination with fulvestrant                                           |
|            |               |                      | Advanced breast cancer [244] (MONARCH 3)                                 | In combination with aromatase inhibitor                                    |
|            |               |                      | NSCLC (KRAS-mutation) [245] (JUNIPER)                                    | In comparison vs. erlotinib                                                |
|            |               |                      | FDA-approved for advanced breast cancer [246]                           |                                |
| Palbociclib | 4, 6 [240]    | Phase I              | Advanced solid tumours [247-249], including pancreatic cancer            | In combination with cisplatin, carboplatin, ulixertinib, gedatolisib        |
|            |               | Phase II             | Advanced breast cancer [250,251]                                         | In combination with anastrozole, letrozole                                  |
|            |               | Phase III            | Advanced breast cancer [252]                                             | In combination with fulvestrant                                           |
|            |               |                      | FDA-approved for advanced breast cancer [253]                           |                                |
| Milciclib   | 1, 2, 4, 5 [257] | Phase I              | Refractory solid tumours [257]                                           |                                |
| Bryostatin-1 | 2 [190,255] | Phase II             | Advanced pancreatic carcinoma [256]                                      | In combination to paclitaxel                                               |
| Milciclib   | 1, 2, 4, 5 [257] | Phase I              | Refractory solid tumours [257]                                           | In combination with gemcitabine                                           |
Flavopiridol (Alvocidib) was one of the first CDK inhibitors, with a wave of publications in the 2000s–2010s. Acting as a pan-CDK-inhibitor (targeting CDK1, 2, 4, 6, 7 and 9) [26], its first results in phase I studies in chronic lymphocytic leukemia (CLL) seemed encouraging, as most of the patients had a reduction in tumour mass; some even had complete responses [27]. Another phase I study, this time in solid tumours, could not confirm this enthusiasm: of 42 subjects, 22 had progression of the disease, 13 had a stable disease, and only seven subjects showed an improvement when flavopiridol was combined with conventional chemotherapy (Oxaliplatin, FOLFOX). Intriguingly, there was one complete response measurable in a case of pancreatic cancer [227]. Another study of this type, with different cytostatics (FOLFIRI; FOL = Folinic acid, F = 5-FU, IRI = Irinotecan), showed similar results [228]. A phase I dose-finding study with docetaxel and flavopiridol in advanced solid tumours showed cases of complete and partial responses towards this regime in pancreatic cancer, but a comparable amount of stable disease [229]. Again, Phase II studies could not confirm these first results. Until now, additional studies have been undertaken in metastatic melanoma, endometrial adenocarcinoma and multiple myeloma, without objective signs of antitumoural activity [190]. Moreover, flavopiridol showed severe adverse effects, and consequently, it was discontinued [240]. Interestingly, flavopiridol in combination with several classical chemotherapeutics, like doxorubicin, docetaxel and FOLFOX (FOL = Folinic acid, F = 5-FU, OX = Oxaliplatin), seems to exacerbate their anti-tumourigenic effect, although this is controversially discussed, as there are also contradictory results on this matter [230,232,258]. One phase II study directed solely towards pancreatic cancer (ClinicalTrials.gov Identifier NCT00331682) showed no benefit from treatment of gemcitabine-refractory, metastatic pancreatic cancer with a combination of docetaxel and flavopiridol [232,233]. Another study (ClinicalTrials.gov Identifier NCT00047307) currently investigates the effects of flavopiridol in combination with radiation, followed by gemcitabine on locally advanced, unresectable pancreatic cancer with no results published so far [231].

Dinaciclib, also acting as a multi-CDK-inhibitor, was first described in 2010 [211]. It showed desirable inhibitory effects towards pancreatic cancer in murine xenograft models [214]. Although clinical studies in humans with pancreatic cancer and dinaciclib are rare, it has been extensively studied in other tumour entities. Dinaciclib is one of the few CDK-inhibitors, next to palbociclib and abemaciclib, which made it past phase II into phase III in CLL [213]. One of the most significant predicted benefits of dinaciclib over flavopiridol is better tolerance over longer timespans, especially in refractory patients [234]. One study showed that with dinaciclib-treatment there is a significant response in CLL patients [234]. Another study demonstrated the efficacy of dinaciclib in relapsed multiple myeloma [237]. In a phase I trial in advanced malignancies dinaciclib was able to stabilise disease while being tolerable over a long time span [212]. In contrast to this, other phase I trials were less favourable. As such, Mitri et al. showed that the combination of dinaciclib with epirubicin could not stop the progression of triple negative breast cancer [235]. Furthermore, this regime came at a price of high toxicity [235]. A phase II study in advanced breast cancer showed capecitabine to be superior over dinaciclib concerning disease-free survival [238]. Dinaciclib showed no antitumoural effects and no superiority over erlotinib in progression-free survival for non-small cell lung cancer in a phase II study [239]. However, most of these studies show good tolerance towards dinaciclib when it is administered as a single drug [212,234,238,239].

Regarding phase III studies, dinaciclib was compared to ofatumumab, an anti-CD-20-antibody [259] in terms of efficacy and safety in relapsed or refractory CLL [213]. This study showed the promising antitumoural activity of dinaciclib in this hematologic neoplasia, with five times better overall response [213]. Currently, there is one already completed phase I study directed towards inoperable pancreatic cancer though there are no results published yet (ClinicalTrials.gov Identifier NCT01783171). In summary, it can be said that while dinaciclib seems like a well tolerable drug, it also seems to show superior anti-tumour activity in non-solid cancers.

SNS-032, a specific inhibitor of CDKs 2, 7, and 9 [219] has only undergone phase I studies until now. It was proven to be tolerable in humans [220]; however, the best clinical response in
advanced solid tumours was stable disease in only 15% of cases, whereas the rest of the cases worsened. Again, another phase I study in the hematologic malignancies CLL and multiple myeloma showed better results for SNS-032 treatment [221].

Abemaciclib is a CDK4/6 inhibitor that has made it into phase III clinical studies and is even FDA-approved for certain advanced breast cancers [246]. This drug showed promising results for solid malignancies in several studies, including the extension of progression-free survival [243], even objective response rates in highly advanced breast cancers [242,244]. The JUNIPER study is of particular interest since it investigates the effects of abemaciclib on KRAS-mutated non-small cell lung cancer [245]. However, currently, there are no results posted (ClinicalTrials.gov Identifier: NCT02152631). Furthermore, there is an ongoing study targeting the effects of abemaciclib alone or in combination with other agents on previously treated PDAC (ClinicalTrials.gov Identifier: NCT02981342).

The CDK4/6 inhibitor palbociclib is FDA-approved for advanced breast cancers, and most literature refers to this substance in breast cancer and most studies investigate the effects of this substance in breast cancer [250–253]. Only a few studies addressing pancreatic cancer exist. These studies investigate the effects of combinatorial treatments with palbociclib on pancreatic cancer: ClinicalTrials.gov Identifier: NCT02897375 (Cisplatin, Carboplatin), ClinicalTrials.gov Identifier: NCT03454035 (ERK1/2 Inhibitor Ulixertinib), ClinicalTrials.gov Identifier: NCT03065062 (PI3K/mTOR Inhibitor gedatolisib). As of now, no results have been posted yet.

There are ongoing studies with a number of other CDK-inhibitors that include pancreatic cancer: Ribociclib (ClinicalTrials.gov Identifier: NCT02703571; no results posted), the macrolide lactone molecule bryostatin-1 (ClinicalTrials.gov Identifier: NCT00031694; known for activation of protein kinase C, but also inhibition of CDK2 [190,255]; not effective in combination with paclitaxel in advanced pancreatic carcinoma) [256], as well as milciclib was reportedly able to overcome gemcitabine-resistance in a pancreatic cancer patients [257].

In summary, while mostly well tolerable, CDK-inhibitors seem to induce improved responses in hematologic malignancies more than in solid tumours. Reasons for this remain to be explored. Although there are many trials currently ongoing to address the role of CDKs in PDAC, there are still a lot of studies necessary to further evaluate the promise of CDK-inhibitors. For example, the identification of biomarkers, other than Rb, that can predict the response to CDK inhibitor therapies is needed, both to understand in a deeper manner the mechanisms of action of these inhibitors and to determine which patients benefit the most from combinatorial therapies.

CDK/cyclin complexes have been extensively studied in the past decades, yet their roles in the cell cycle and other related processes are not fully understood. It is likely that new functions of CDK/cyclin complexes will be discovered, adding more layers of complexity to the biological consequences of their inhibition, but also shedding more light into the mechanisms of tumorigenesis involved when these proteins expression and activity are altered. As CDK dysregulation is associated with tumorigenesis, these protein remain as an exciting target for therapeutic inhibition. In pancreatic cancer, there is an urgent need for treatment alternatives, and inhibition of CDKs represent a possible approach against this deadly disease.

Author Contributions: B.G.-R., A.-L.K., J.L. and D.H.-B. designed the study. B.G.-R., A.-L.K., J.-P.R. performed the literature search. A.-L.K., B.G.-R. and J.L. prepared the figures. B.G.-R., A.-L.K., A.H., J.-P.R., U.K. and S.v.K. wrote the manuscript. All authors contributed to the preparation of the manuscript. All authors read and approved the manuscript.

Funding: This research was funded by a Deutsche Forschungsgemeinschaft research grant (LE3556/1-1) awarded to J.L. S.v.K. is funded through the Max Eder grant of the Deutsche Krebshilfe.

Conflicts of Interest: The authors declare no conflict of interest.
Abbreviations

CAK  CDK-activating kinase
CDK  Cyclin-dependent kinase
CDKN2A  Cyclin-dependent kinase Inhibitor 2A
CLL  Chronic lymphocytic leukemia
CMGC  CDKs, MAPKs, Gsk3β, and CDK-like kinases
CTD  C-Terminal Domain
DYRK  Dual-specificity tyrosine-regulated kinase
ELL2  Elongation Factor for RNA Polymerase II
FACT protein  Facilitates chromatin transcription
FDA  US Food and Drug Administration
FOLFIRINOX  FOL = Folinic acid, L = Leucovorin, F = 5-FU = 5-Fluorouracil, IRIN = Irinotecan, OX = Oxaliplatin
FoxM1  Forkhead box protein M1
GADD45  Growth Arrest and DNA Damage-inducible protein
GSK3β  Glycogen synthase kinase-3 β
hESC  Human embryonic stem cells
hiPSC  Human induced pluripotent stem cells
INK4  Inhibitor of Cyclin-Dependent Kinase 4
MAPK  Mitogen-activated protein kinase
MAT1  Menage à trois 1
Mcl-1  Myeloid leukaemia cell differentiation protein 1
MED12  Mediator complex subunit 12
MED13  Mediator complex subunit 13
MPK7  Mitogen-activated protein kinase 7
mTOR  Mechanistic target of rapamycin
NSCLC  Non-small cell lung cancer
PanIN  Pancreatic intraepithelial neoplasia
PDAC  Pancreatic ductal adenocarcinoma
pTEFb  Positive transcription elongation factor b
RalA  RAS-Like Protein A
Rb  Retinoblastoma protein
RNA Pol II  RNA polymerase II
ROS  Reactive oxygen species
TAK  Tat-associated kinase
TCF/LEF  T-cell factor/lymphoid enhancer factor
TF  Transcription factor
TFIIH  Transcription factor II H
TP53  Tumour protein p53
TPKII  Tau protein kinase II
TRAIL-R1/2  Tumour necrosis factor-related, apoptosis-inducing ligand receptors 1/2

References

1. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2017. *CA Cancer J. Clin.* **2017**, *67*, 7–30. [CrossRef] [PubMed]
2. Hidalgo, M. Pancreatic Cancer. *N. Engl. J. Med.* **2010**, *362*, 1605–1617. [CrossRef] [PubMed]
3. Kleeff, J.; Korc, M.; Apte, M.; La Vecchia, C.; Johnson, C.D.; Biankin, A.V.; Neale, R.E.; Tempero, M.; Tuveson, D.A.; Hruban, R.H.; et al. Pancreatic cancer. *Nat. Rev. Dis. Primers* **2016**, *2*, 16022. [CrossRef] [PubMed]
4. Simoes, P.K.; Olson, S.H.; Saldia, A.; Kurtz, R.C. Epidemiology of pancreatic adenocarcinoma. *Chin. Clin. Oncol.* **2017**, *6*, 24. [CrossRef] [PubMed]
1. Johnstone, R.W.; Ruefli, A.A.; Lowe, S.W. Apoptosis: A link between cancer genetics and chemotherapy. Cell 2002, 108, 153–164. [CrossRef]
2. Conroy, T.; Bachet, J.-B.; Ayav, A.; Huguet, F.; Lambert, A.; Caramella, C.; Marechal, R.; Van Laethem, J.-L.; Dureu, M. Current standards and new innovative approaches for treatment of pancreatic cancer. Eur. J. Cancer 2016, 57, 10–22. [CrossRef] [PubMed]
3. Kretz, A.-L.; von Karstedt, S.; Hillenbrand, A.; Henne-Bruns, D.; Knippschild, U.; Lemke, J. Should We Keep Walking along the Trail for Pancreatic Cancer Treatment? Revisiting TNF-Related Apoptosis-Inducing Ligand for Anticancer Therapy. Cancers 2018, 10, 77. [CrossRef] [PubMed]
4. Unicancer GI PRODIGE 24/CCTG PA.6 Trial: A Multicenter International Randomized Phase III Trial of Adjuvant mFOLFIRINOX versus Gemcitabine (gem) in Patients with Resected Pancreatic Ductal Adenocarcinomas. 2018 ASCO Annual Meeting Abstracts. Available online: http://abstracts.asco.org/214/AbstView_214_218335.html (accessed on 2 August 2018).
5. Conroy, T.; Desseigne, F.; Ychou, M.; Bouché, O.; Guimbaud, R.; Bécouarn, Y.; Adenis, A.; Raoul, J.-L.; Gourgou-Bourgade, S.; de la Fouharidiére, C.; et al. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. N. Engl. J. Med. 2011, 364, 1817–1825. [CrossRef] [PubMed]
6. Assaf, E.; Verlinde-Carvalho, M.; Delbaldo, C.; Grenier, J.; Sellam, Z.; Poussel, D.; Bouaita, L.; Baumgaertner, J.; Sobhani, I.; Tayar, C.; et al. 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma. Oncology 2011, 80, 301–306. [CrossRef] [PubMed]
7. de W Marsh, R.; Talamonti, M.S.; Baker, M.S.; Posner, M.; Roggin, K.; Matthews, J.; Catenacci, D.; Kozloff, M.; Polite, B.; Britto, M.; et al. Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: A pilot study. J. Surg. Oncol. 2018, 117, 354–362. [CrossRef] [PubMed]
8. Gunturu, K.S.; Yao, X.; Cong, X.; Thumar, J.R.; Hochster, H.S.; Stein, S.M.; Lacy, J. FOLFIRINOX for locally advanced and metastatic pancreatic cancer: Single institution retrospective review of efficacy and toxicity. Med. Oncol. 2013, 30, 361. [CrossRef] [PubMed]
49. Tsai, L.H.; Harlow, E.; Meyerson, M. Isolation of the human cdk2 gene that encodes the cyclin A- and adenovirus E1A-associated p33 kinase. *Nature* 1991, 353, 174–177. [CrossRef] [PubMed]

50. Sheaff, R.J.; Groudine, M.; Gordon, M.; Roberts, J.M.; Clurman, B.E. Cyclin E-CDK2 is a regulator of p27Kip1. *Genes Dev.* 1997, 11, 1464–1478. [CrossRef] [PubMed]

51. Hinchcliffe, E.H.; Li, C.; Thompson, E.A.; Maller, J.L.; Sluder, G. Requirement of Cdk2-cyclin E activity for repeated centrosome reproduction in Xenopus egg extracts. *Science* 1999, 283, 851–854. [CrossRef] [PubMed]

52. Matsumoto, Y.; Maller, J.L. A centrosomal localization signal in cyclin E required for Cdk2-independent S phase entry. *Science* 2004, 306, 889–888. [CrossRef] [PubMed]

53. Zariwala, M.; Liu, J.; Xiong, Y. Cyclin E2, a novel human G1 cyclin and activating partner of CDK2 and CDK3, is induced by viral oncoproteins. *Oncogene* 1998, 17, 2787–2798. [CrossRef] [PubMed]

54. Ye, X.; Zhu, C.; Harper, J.W. A premature-termination mutation in the Mus musculus cyclin-dependent kinase 3 gene. *Proc. Natl. Acad. Sci. USA* 2001, 98, 1682–1686. [CrossRef] [PubMed]

55. Ren, S.; Rollins, B.J. Cyclin C/cdk3 promotes Rb-dependent G0 exit. *Cell* 2004, 117, 239–251. [CrossRef]

56. Harbour, J.W.; Luo, R.X.; Dei Santi, A.; Postigo, A.A.; Dean, D.C. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. *Cell* 1999, 98, 859–869. [CrossRef]

57. Lazarov, M.; Kubo, Y.; Cai, T.; Dajee, M.; Tarutani, M.; Lin, Q.; Fang, M.; Tao, S.; Green, C.L.; Khavari, P.A. CDK4 coexpression with Ras generates malignant human epidermal tumorigenesis. *Nat. Med.* 2002, 8, 1105–1114. [CrossRef] [PubMed]

58. Matsuura, I.; Denissova, N.G.; Wang, G.; He, D.; Long, J.; Liu, F. Cyclin-dependent kinases regulate the antiproliferative function of Smads. *Nature* 2004, 430, 226–231. [CrossRef] [PubMed]

59. Meyerson, M.; Harlow, E. Identification of G1 kinase activity for cdk6, a novel cyclin D partner. *Mol. Cell Biol.* 1994, 14, 2077–2086. [CrossRef] [PubMed]

60. Veiga-Fernandes, H.; Rocha, B. High expression of active CDK6 in the cytoplasm of CD8 memory cells favors rapid division. *Nat. Immunol.* 2004, 5, 31–37. [CrossRef] [PubMed]

61. Patrick, G.N.; Zukerberg, L.; Nikolic, M.; de la Monte, S.; Dikkes, P.; Tsai, L.H. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. *Nature* 1999, 402, 615–622. [CrossRef] [PubMed]

62. Dhavan, R.; Tsai, L.H. A decade of CDK5. *Nat. Rev. Mol. Cell Biol.* 2004, 5, 547–551. [CrossRef] [PubMed]

63. Shankland, S.J. Cyclin I activates Cdk5 and regulates expression of Bcl-2 and Bcl-XL in postmitotic mouse cells. *J. Clin. Investig.* 2009, 119, 3089–3101. [CrossRef] [PubMed]

64. Nagano, T.; Hashimoto, T.; Nakashima, A.; Hisanaga, S.; Kikkawa, U.; Kamada, S. Cyclin I is involved in the regulation of cell cycle progression. *Cell Cycle* 2013, 12, 2617–2624. [CrossRef] [PubMed]

65. Fisher, R.P.; Morgan, D.O. A novel cyclin associates with MO15/CDK7 to form the CDK-activating kinase. *Cell* 1994, 78, 713–724. [CrossRef]

66. Shiekhattar, R.; Mermelstein, F.; Fisher, R.P.; Drapkin, R.; Dynlacht, B.; Wessling, H.C.; Morgan, D.O.; Reinberg, D. Cdk-activating kinase complex is a component of human transcription factor TFIH. *Nature* 1995, 374, 283–287. [CrossRef] [PubMed]

67. Akoulitchev, S.; Chuikov, S.; Reinberg, D. TFIH is negatively regulated by cdk8-containing mediator complexes. *Nature* 2000, 407, 102–106. [CrossRef] [PubMed]

68. Tassan, J.P.; Jaquenoud, M.; Leopold, P.; Schultz, S.J.; Nigg, E.A. Identification of human cyclin-dependent kinase 8, a putative protein kinase partner for cyclin C. *Proc. Natl. Acad. Sci. USA* 1995, 92, 8871–8875. [CrossRef] [PubMed]

69. Firestein, R.; Bass, A.J.; Kim, S.Y.; Dunn, I.F.; Silver, S.J.; Guney, I.; Freed, E.; Ligon, A.H.; Vena, N.; Ogino, S.; et al. Cdk8 is a colorectal cancer oncogene that regulates β-catenin activity. *Nature* 2008, 455, 547–551. [CrossRef] [PubMed]

70. Tsutsui, T.; Fukasawa, R.; Tanaka, A.; Hirose, Y.; Ohkuma, Y. Identification of target genes for the CDK subunits of the Mediator complex. *Genes Cells* 2011, 16, 1208–1218. [CrossRef] [PubMed]

71. Shore, S.M.; Byers, S.A.; Maury, W.; Price, D.H. Identification of a novel isoform of Cdk9. *Gene* 2003, 307, 175–182. [CrossRef]

72. Garriga, J.; Grana, X. Cellular control of gene expression by T-type cyclin/CDK9 complexes. *Gene* 2004, 337, 15–23. [CrossRef] [PubMed]
73. Guen, V.J.; Gamble, C.; Flajolet, M.; Unger, S.; Thollet, A.; Ferandin, Y.; Superti-Furgia, A.; Cohen, P.A.; Meijer, L.; Colas, P. CDK10/cyclin M is a protein kinase that controls ETS2 degradation and is deficient in STAR syndrome. Proc. Natl. Acad. Sci. USA 2013, 110, 19525–19530. [CrossRef] [PubMed]
74. Chen, H.H.; Wang, Y.C.; Fann, M.J. Identification and characterization of the CDK12/cyclin L1 complex involved in alternative splicing regulation. Mol. Cell. Biol. 2006, 26, 2736–2745. [CrossRef] [PubMed]
75. Yu, M.; Yang, W.; Ni, T.; Tang, Z.; Nakadai, T.; Zhu, J.; Roeder, R.G. RNA polymerase II-associated factor 1 regulates the release and phosphorylation of paused RNA polymerase II. Science 2015, 350, 1383–1386. [CrossRef] [PubMed]
76. Kohoutek, J.; Blazek, D. Cyclin K goes with Cdk12 and Cdk13. Cell Div. 2012, 7, 12. [CrossRef] [PubMed]
77. Hu, D.; Mayeda, A.; Trembley, J.H.; Lahti, J.M.; Kidd, V.J. CDK11 complexes promote pre-mRNA splicing. J. Biol. Chem. 2003, 278, 8623–8629. [CrossRef] [PubMed]
78. Loyer, P.; Trembley, J.H.; Grenet, J.A.; Busson, A.; Corlu, A.; Zhao, W.; Kocak, M.; Kidd, V.J.; Lahti, J.M. Characterization of cyclin L1 and L2 interactions with CDK11 and splicing factors: Influence of cyclin L isoforms on splice site selection. J. Biol. Chem. 2008, 283, 7721–7732. [CrossRef] [PubMed]
79. Davidson, G.; Shen, J.; Huang, Y.L.; Su, Y.; Karaulanov, E.; Bartscherer, K.; Hassler, C.; Stannen, P.; Boutros, M.; Niehrs, C. Cell cycle control of wnt receptor activation. Dev. Cell 2009, 17, 788–799. [CrossRef] [PubMed]
80. Romano, G. Deregulations in the cyclin-dependent kinase-9-related pathway in cancer: Implications for drug discovery and development. ISRN Oncol. 2013, 2013, 305371. [CrossRef] [PubMed]
81. Park, M.H.; Kim, S.Y.; Kim, Y.J.; Chung, Y.H. ALS2CR7 (CDK15) attenuates TRAIL induced apoptosis by inducing phosphorylation of survivin Thr34. Biochem. Biophys. Res. Commun. 2014, 450, 129–134. [CrossRef] [PubMed]
82. Dixon-Clarke, S.E.; Shehata, S.N.; Krojer, T.; Sharpe, T.D.; von Delft, F.; Sakamoto, K.; Bullock, A.N. Structure and inhibitor specificity of the PCTAIRE-family kinase CDK16. Biochem. J. 2017, 474, 699–713. [CrossRef] [PubMed]
83. Hirose, T.; Tamaru, T.; Okumura, N.; Nagai, K.; Okada, M. PCTAIRE-2, a Cdc2-related serine/threonine kinase, is predominantly expressed in terminally differentiated neurons. Eur. J. Biochem. 1997, 249, 481–488. [CrossRef] [PubMed]
84. Besset, V.; Rhee, K.; Wolgemuth, D.J. The cellular distribution and kinase activity of the Cdk family member Pctaire1 in the adult mouse brain and testis suggest functions in differentiation. Cell Growth Differ. 1999, 10, 173–181. [PubMed]
85. Okuda, T.; Cleveland, J.L.; Downing, J.R. PCTAIRE-1 and PCTAIRE-2, two members of a novel cdc2/CDCC28-related protein kinase gene family. Oncogene 1992, 7, 2249–2258. [PubMed]
86. Barone, G.; Staples, C.J.; Ganesh, A.; Patterson, K.W.; Bryne, D.P.; Myers, K.N.; Patil, A.A.; Eyers, C.E.; Maslen, S.; Skehel, J.M.; et al. Human CDK18 promotes replication stress signaling and genome stability. Nucleic Acids Res. 2016, 44, 8772–8785. [CrossRef] [PubMed]
87. Matsuda, S.; Kawamoto, K.; Miyamoto, K.; Tsuji, A.; Yuasa, K. PCTK3/CDK18 regulates cell migration and adhesion by negatively modulating FAK activity. Sci. Rep. 2017, 7, 45545. [CrossRef] [PubMed]
88. Wohlbold, L.; Larochelle, S.; Liao, J.C.; Livshits, G.; Singer, J.; Shokat, K.M.; Fisher, R.P. The cyclin-dependent kinase (CDK) family member PNQALRE/CCRK supports cell proliferation but has no intrinsic CDK-activating kinase (CAK) activity. Cell Cycle 2006, 5, 546–554. [CrossRef] [PubMed]
89. Wang, Q.; Ma, J.; Lu, Y.; Zhang, S.; Huang, J.; Chen, J.; Bei, J.X.; Yang, K.; Wu, G.; Huang, K.; et al. CDK20 interacts with KEAP1 to activate NRF2 and promotes radiochemoresistance in lung cancer cells. Oncogene 2017, 36, 5321–5330. [CrossRef] [PubMed]
90. Alexander, S.P.; Fabbro, D.; Kelly, E.; Marrion, N.V.; Peters, J.A.; Faccenda, E.; Harding, S.D.; Pawson, A.J.; Sharman, J.L.; Southan, C.; et al. The Concise Guide to Pharmacology 2017/18: Enzymes. Br. J. Pharmacol. 2017, 174 (Suppl. 1), S272–S359. [CrossRef] [PubMed]
91. Tang, D.; Chun, A.C.; Zhang, M.; Wang, J.H. Cyclin-dependent kinase 5 (Cd5) activation domain of neuronal Cd5 activator. Evidence of the existence of cyclin fold in neuronal Cd5a activator. J. Biol. Chem. 1997, 272, 12318–12327. [CrossRef] [PubMed]
92. Chou, K.C.; Watenpaugh, K.D.; Heinrikson, R.L. A model of the complex between cyclin-dependent kinase 5 and the activation domain of neuronal Cd5 activator. Biochem. Biophys. Res. Commun. 1999, 259, 420–428. [CrossRef] [PubMed]
117. Nyberg, K.A.; Michelson, R.J.; Putnam, C.W.; Weinert, T.A. Toward maintaining the genome: DNA damage and replication checkpoints. *Annu. Rev. Genet.* 2002, 36, 617–656. [CrossRef] [PubMed]

118. Trimarchi, J.M.; Lees, J.A. Sibling rivalry in the E2F family. *Nat. Rev. Mol. Cell Biol.* 2002, 3, 11–20. [CrossRef] [PubMed]

119. Chen, Y.J.; Dominguez-Brauer, C.; Wang, Z.; Asara, J.M.; Costa, R.H.; Tyner, A.L.; Lau, L.F.; Raychaudhuri, P. A conserved phosphorylation site within the forhead domain of FoxM1B is required for its activation by cyclin-CDK1. *J. Biol. Chem.* 2009, 284, 30695–30707. [CrossRef] [PubMed]

120. Major, M.L.; Lepe, R.; Costa, R.H. Forkhead box M1B transcriptional activity requires binding of Cdk-cyclin complexes for phosphorylation-dependent recruitment of p300/CBP coactivators. *Mol. Cell. Biol.* 2004, 24, 2649–2661. [CrossRef] [PubMed]

121. Laoukili, J.; Alvarez, M.; Meijer, L.A.; Mohammed, S.; Kleij, L.; Heck, A.J.; Medema, R.H. Activation of FoxM1 during G2 requires cyclin A/Cdk-dependent relief of autorepression by the FoxM1 N-terminal domain. *Mol. Cell. Biol.* 2008, 28, 3076–3087. [CrossRef] [PubMed]

122. Park, H.J.; Wang, Z.; Costa, R.H.; Tyner, A.; Lau, L.F.; Raychaudhuri, P. An N-terminal inhibitory domain modulates activity of FoxM1 during cell cycle. *Oncogene* 2008, 27, 1696–1704. [CrossRef] [PubMed]

123. Rickert, P.; Corden, J.L.; Lees, E. Cyclin C/CDK8 and cyclin H/CDK7/p36 are biochemically distinct CTD kinases. *Oncogene* 1999, 18, 1093–1102. [CrossRef] [PubMed]

124. Carlsten, J.O.; Zhu, X.; Gustafsson, C.M. The multitalented Mediator complex. *Trends Biochem. Sci.* 2013, 38, 531–537. [CrossRef] [PubMed]

125. Nemet, J.; Jelicic, B.; Rubelj, I.; Sopta, M. The two faces of Cdk8, a positive/negative regulator of transcription. *Biochimie* 2014, 97, 22–27. [CrossRef] [PubMed]

126. Serizawa, H.; Makela, T.P.; Conaway, J.W.; Conaway, R.C.; Weinberg, R.A.; Young, R.A. Association of Oqani, R.K.; Kim, H.R.; Diao, Y.F.; Park, C.S.; Jin, D.I. The CDK9/cyclin T1 subunits of P-TEFb in mouse 3. *J. Biol. Chem.* 2014, 289, 5573–5585. [CrossRef] [PubMed]

127. Peng, J.; Liu, M.; Marion, J.; Zhu, Y.; Price, D.H. RNA polymerase II elongation control. *Cold Spring Harb. Symp. Quant. Biol.* 1998, 63, 365–370. [CrossRef] [PubMed]

128. Fu, T.J.; Peng, J.; Lee, G.; Price, D.H.; Flores, O. Cyclin K functions as a CDK9 regulatory subunit and participates in RNA polymerase II transcription. *J. Biol. Chem.* 1999, 274, 34527–34530. [CrossRef] [PubMed]

129. Oqani, R.K.; Kim, H.R.; Diao, Y.F.; Park, C.S.; Jin, D.I. The CDK9/cyclin T1 subunits of P-TEFb in mouse oocytes and preimplantation embryos: A possible role in embryonic genome activation. *BMC Dev. Biol.* 2011, 11, 33. [CrossRef] [PubMed]

130. Zhou, Q.; Yik, J.H. The Yin and Yang of P-TEFb regulation: Implications for human immunodeficiency virus gene expression and global control of cell growth and differentiation. *Microbiol. Mol. Biol. Rev.* 2006, 70, 646–659. [CrossRef] [PubMed]

131. Dickinson, L.A.; Edgar, A.J.; Ehley, J.; Gottesfeld, J.M. Cyclin L is an RS domain protein involved in pre-mRNA splicing. *J. Biol. Chem.* 2002, 277, 25465–25473. [CrossRef] [PubMed]

132. Bartkowski, B.; Liu, P.; Phatnani, H.P.; Fuda, N.J.; Cooper, J.J.; Price, D.H.; Adelman, K.; Lis, J.T.; Greenleaf, A.L. CDK12 is a transcription elongation-associated CTD kinase, the metazoan ortholog of yeast Ctk1. *Genes Dev.* 2010, 24, 2303–2316. [CrossRef] [PubMed]

133. Cheng, S.W.; Kuzyk, M.A.; Moradian, A.; Ichu, T.A.; Chang, V.C.; Tien, J.F.; Vollett, S.E.; Griffith, M.; Marra, M.; Morin, G.B. Interaction of cyclin-dependent kinase 12/CrkRS with cyclin K1 is required for the phosphorylation of the C-terminal domain of RNA polymerase II. *Mol. Cell. Biol.* 2012, 32, 4691–4704. [CrossRef] [PubMed]

134. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. *Cell* 2011, 144, 646–674. [CrossRef] [PubMed]

135. Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. *Cell* 2000, 100, 57–70. [CrossRef]

136. Bukholm, I.R.; Bukholm, G.; Nesland, J.M. Over-expression of cyclin A is highly associated with early relapse and reduced survival in patients with primary breast carcinomas. *Int. J. Cancer* 2001, 93, 283–287. [CrossRef] [PubMed]

137. Yam, C.H.; Fung, T.K.; Poon, R.Y. Cyclin A in cell cycle control and cancer. *Cell. Mol. Life Sci.* 2002, 59, 1317–1326. [CrossRef] [PubMed]
139. Kretz, A.L.; Schaum, M.; Richter, J.; Kitzig, E.F.; Engler, C.C.; Leithauser, F.; Henne-Bruns, D.; Knippschild, U.; Lemke, J. CDK9 is a prognostic marker and therapeutic target in pancreatic cancer. *Tumour Biol.* **2017**, *39*, 157. [CrossRef] [PubMed]

140. Ju, H.Q.; Ying, H.; Tian, T.; Ling, J.; Fu, J.; Lu, Y.; Wu, M.; Yang, L.; Acheja, A.; Chen, G.; et al. Mutant Kras and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma. *Nat. Commun.* **2017**, *8*, 14437. [CrossRef] [PubMed]

141. Caldas, C.; Hahn, S.A.; da Costa, L.T.; Redston, M.S.; Schutte, M.; Seymour, A.B.; Weinstein, C.L.; Hruban, R.H.; Yeo, C.J.; Kern, S.E. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. *Nat. Genet.* **1994**, *8*, 27–32. [CrossRef] [PubMed]

142. Chang, D.K.; Grimmond, S.M.; Blankin, A.V. Pancreatic cancer genomics. *Curr. Opin. Genet. Dev.* **2014**, *24*, 74–81. [CrossRef] [PubMed]

143. Hruban, R.H.; Wilentz, R.E.; Kern, S.E. Genetic progression in the pancreatic ducts. *Am. J. Pathol.* **2000**, *156*, 1821–1825. [CrossRef]

144. LaPak, K.M.; Burd, C.E. The molecular balancing act of p16(INK4a) in cancer and aging. *Mol. Cancer Res.* **2014**, *12*, 167–183. [CrossRef] [PubMed]

145. Sherr, C.J. Cancer cell cycles. *Science* **1996**, *274*, 1672–1677. [CrossRef] [PubMed]

146. Burkhardt, D.L.; Sage, J. Cellular mechanisms of tumour suppression by the retinoblastoma gene. *Nat. Rev. Cancer* **2008**, *8*, 671–682. [CrossRef] [PubMed]

147. Hamilton, E.; Infante, J.R. Targeting CDK4/6 in patients with cancer. *Cancer Treat. Rev.* **2016**, *45*, 129–138. [CrossRef] [PubMed]

148. Zinczuk, J.; Zareba, K.; Guzinska-Ustymowicz, K.; Jedrak, B.; Kemeny, A.; Przyczynicz, A. p16, p21, and p53 proteins play an important role in development of pancreatic intraepithelial neoplastic. *Ir. J. Med. Sci.* **2010**, *187*, 629–637. [CrossRef] [PubMed]

149. Goldstein, A.M.; Fraser, M.C.; Struewing, J.P.; Hussussian, C.J.; Ranade, K.; Zametkin, D.P.; Fontaine, L.S.; Zinczuk, J.; Zareba, K.; Guzinska-Ustymowicz, K.; Kedra, B.; Kemona, A.; Pryczynicz, A. p16, p21, and p53 proteins play an important role in development of pancreatic intraepithelial neoplastic. *Ir. J. Med. Sci.* **2010**, *187*, 629–637. [CrossRef] [PubMed]

150. Serrano, M.; Lin, A.W.; McCurrach, M.E.; Beach, D.; Lowe, S.W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. *N. Engl. J. Med.* **1995**, *333*, 970–974. [CrossRef] [PubMed]

151. Sandeno, M.; Lin, A.W.; McCurrach, M.E.; Beach, D.; Lowe, S.W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. *Cell* **1997**, *88*, 593–602. [CrossRef]

152. Bartkova, J.; Rezaei, N.; Liontos, M.; Karakaidos, P.; Kletsas, D.; Issaeva, N.; Vassiliou, L.V.; Kolettas, E.; Niforou, K.; Zoumpourlis, V.C.; et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. *Nature* **2006**, *444*, 633–637. [CrossRef] [PubMed]

153. Collado, M.; Serrano, M. Senescence in tumours: Evidence from mice and humans. *Nat. Rev. Cancer* **2010**, *10*, 51–57. [CrossRef] [PubMed]

154. Xia, Y.; Zhang, H.; Beach, D. D type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA. *Cell* **1992**, *71*, 505–514. [CrossRef]

155. Serrano, M.; Hannon, G.J.; Beach, D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. *Nature* **1993**, *366*, 704–707. [CrossRef] [PubMed]

156. Sherr, C.J. Mammalian G1 cyclins. *Curr. Opin. Genet. Dev.* **1993**, *3*, 704–707. [CrossRef] [PubMed]

157. Witkiewicz, A.K.; Borja, N.A.; Franco, J.; Brody, J.R.; Yeo, C.J.; Mansour, J.; Choti, M.A.; McCue, P.; Knudsen, E.S. Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer. *Oncotarget* **2015**, *6*, 15788–15801. [CrossRef] [PubMed]

158. Chicas, A.; Wang, X.; Zhang, C.; McCurrach, M.; Zhao, Z.; Mert, O.; Dickins, R.A.; Narita, M.; Zhang, M.; Lowe, S.W. Dissecting the unique role of the retinoblastoma tumor suppressor during cellular senescence. *Cell Cycle* **2010**, *9*, 376–387. [CrossRef] [PubMed]

159. Whelan, A.J.; Bartsch, D.; Goodfellow, P.J. Brief report: A familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. *N. Engl. J. Med.* **1995**, *333*, 975–977. [CrossRef] [PubMed]

160. Eggers, J.P.; Grandgenett, P.M.; Collisson, E.C.; Lewallen, M.E.; Tremayne, J.; Singh, P.K.; Swanson, B.J.; Andersen, J.M.; Caffrey, T.C.; High, R.R.; et al. Cyclin-dependent kinase 5 is amplified and overexpressed in pancreatic cancer and activated by mutant K-Ras. *Clin. Cancer Res.* **2011**, *17*, 6140–6150. [CrossRef] [PubMed]
166. Van den Heuvel, S.; Harlow, E. Distinct roles for cyclin-dependent kinases in cell cycle control. *Cell. Biol.* 2001, 13, 738–747. [CrossRef] [PubMed]

167. Bartek, J.; Lukas, J. Mammalian G1- and S-phase checkpoints in response to DNA damage. *Oncogene* 2004, 23, 973–980. [CrossRef] [PubMed]

168. Wierod, L.; Rosseland, C.M.; Lindeman, B.; Oksvold, M.P.; Grosvik, H.; Skarpen, E.; Huitfeldt, H.S. Activation of the p53-p21(Cip1) pathway is required for CDK2 activation and S-phase entry in primary rat hepatocytes. *Oncogene* 2005, 24, 2929–2943. [CrossRef] [PubMed]

169. Calbo, J.; Serna, C.; Garriga, J.; Grana, X.; Mazo, A. The fate of pancreatic tumor cell lines following p16 overexpression depends on the modulation of CDK2 activity. *Cell Death Differ.* 2004, 11, 1055–1065. [CrossRef] [PubMed]

170. van den Heuvel, S.; Harlow, E. Distinct roles for cyclin-dependent kinases in cell cycle control. *Science* 1993, 262, 2050–2054. [CrossRef] [PubMed]

171. Katsuda, K.; Kataoka, M.; Uno, F.; Murakami, T.; Kondo, T.; Roth, J.A.; Tanaka, N.; Fujiwara, T. Activation of caspase-3 and cleavage of Rb are associated with p16-mediated apoptosis in human non-small cell lung cancer cells. *Oncogene* 2002, 21, 2108–2113. [CrossRef] [PubMed]

172. Kim, M.; Katayose, Y.; Rojanala, L.; Shah, S.; Sgagias, M.; Jang, L.; Jung, Y.J.; Lee, S.H.; Hwang, S.G.; Cowan, K.H. Induction of apoptosis in p16INK4A mutant cell lines by adenovirus-mediated overexpression of p16INK4A protein. *Cell Death Differ.* 2000, 7, 706–711. [CrossRef] [PubMed]

173. O’Connor, P.M. Mammalian G1 and G2 phase checkpoints. *Cancer Surv.* 1997, 29, 151–182. [PubMed]

174. Bartek, J.; Lukas, J. Mammalian G1- and S-phase checkpoints in response to DNA damage. *Curr. Opin. Cell Biol.* 2001, 13, 738–747. [CrossRef] [PubMed]

175. Calbo, J.; Serna, C.; Garriga, J.; Grana, X.; Mazo, A. The fate of pancreatic tumor cell lines following p16 overexpression depends on the modulation of CDK2 activity. *Cell Death Differ.* 2004, 11, 1055–1065. [CrossRef] [PubMed]

176. van den Heuvel, S.; Harlow, E. Distinct roles for cyclin-dependent kinases in cell cycle control. *Science* 1993, 262, 2050–2054. [CrossRef] [PubMed]

177. Katsuda, K.; Kataoka, M.; Uno, F.; Murakami, T.; Kondo, T.; Roth, J.A.; Tanaka, N.; Fujiwara, T. Activation of caspase-3 and cleavage of Rb are associated with p16-mediated apoptosis in human non-small cell lung cancer cells. *Oncogene* 2002, 21, 2108–2113. [CrossRef] [PubMed]

178. Kim, M.; Katayose, Y.; Rojanala, L.; Shah, S.; Sgagias, M.; Jang, L.; Jung, Y.J.; Lee, S.H.; Hwang, S.G.; Cowan, K.H. Induction of apoptosis in p16INK4A mutant cell lines by adenovirus-mediated overexpression of p16INK4A protein. *Cell Death Differ.* 2000, 7, 706–711. [CrossRef] [PubMed]

179. Jeannot, P.; Callot, C.; Baer, R.; Duquesnes, N.; Guerra, C.; Guillermet-Guibert, J.; Bachs, O.; Besson, A. Loss of p27Kip(1) promotes metaplasia in the pancreas via the regulation of Sox9 expression. *Oncotarget* 2015, 6, 35880–35892. [CrossRef] [PubMed]
180. Lukas, J.; Herzinger, T.; Hansen, K.; Moroni, M.C.; Resnitzky, D.; Helin, K.; Reed, S.I.; Bartek, J. Cyclin E-induced S phase without activation of the pRb/E2F pathway. *Genes Dev.* 1997, 11, 1479–1492. [CrossRef] [PubMed]

181. Alevizopoulos, K.; Vlach, J.; Hennecke, S.; Amati, B. Cyclin E and c-Myc promote cell proliferation in the presence of p16INK4a and of hypophosphorylated retinoblastoma family proteins. *EMBO J.* 1997, 16, 5322–5333. [CrossRef] [PubMed]

182. Neganova, I.; Tilgner, K.; Buskin, A.; Paraskevopoulou, I.; Atkinson, S.P.; Peberdy, D.; Passos, J.F.; Lako, M. CDK1 plays an important role in the maintenance of pluripotency and genomic stability in human pluripotent stem cells. *Cell Death Dis.* 2014, 5, e1508. [CrossRef] [PubMed]

183. Vassilev, L.T.; Tovar, C.; Chen, S.; Knezovic, D.; Zhao, X.; Sun, H.; Heimbrook, D.C.; Chen, L. Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1. *Proc. Natl. Acad. Sci. USA* 2006, 103, 10660–10665. [CrossRef] [PubMed]

184. Diril, M.K.; Ratnakaram, C.K.; Padmakumar, V.C.; Du, T.; Wasser, M.; Coppola, V.; Tessarollo, L.; Kaldis, P. Cyclin-dependent kinase 1 (Cdk1) is essential for cell division and suppression of DNA re-replication but not for liver regeneration. *Proc. Natl. Acad. Sci. USA* 2012, 109, 3826–3831. [CrossRef] [PubMed]

185. Berthet, C.; Kaldis, P. Cell-specific responses to loss of cyclin-dependent kinases. *Oncogene* 2007, 26, 4469–4477. [CrossRef] [PubMed]

186. Guo, J.; Kleeff, J.; Li, J.; Ding, J.; Hammer, J.; Zhao, Y.; Giese, T.; Korc, M.; Buchler, M.W.; Friess, H. Expression and functional significance of CDC25B in human pancreatic ductal adenocarcinoma. *Oncogene* 2004, 23, 71–81. [CrossRef] [PubMed]

187. Fisher, R.P. Secrets of a double agent: CDK7 in cell-cycle control and transcription. *J. Cell Sci.* 2005, 118, 5171–5180. [CrossRef] [PubMed]

188. Wang, S.; Fischer, P.M. Cyclin-dependent kinase 9: A key transcriptional regulator and potential drug target in oncology, virology and cardiology. *Trends Pharmacol. Sci.* 2008, 29, 302–313. [CrossRef] [PubMed]

189. Malumbres, M.; Pevarello, P.; Barbacid, M.; Bischoff, J.R. CDK inhibitors in cancer therapy: What is next? *Trends Pharmacol. Sci.* 2008, 29, 16–21. [CrossRef] [PubMed]

190. Dickson, M.A.; Schwartz, G.K. Development of cell-cycle inhibitors for cancer therapy. *Curr. Oncol.* 2009, 16, 36–43. [PubMed]

191. Lemke, J.; Schäfer, D.; Sander, S.; Henne-Bruns, D.; Kormann, M. Survival and prognostic factors in pancreatic and ampullary cancer. *Anticancer Res.* 2014, 34, 3011–3020. [PubMed]

192. Fry, D.W.; Harvey, P.J.; Keller, P.R.; Elliott, W.L.; Meade, M.; Trachet, E.; Albassam, M.; Zheng, X.; Leopold, W.R.; Pryer, N.K.; et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. *Mol. Cancer Ther.* 2004, 3, 1427–1438. [PubMed]

193. Rader, J.; Russell, M.R.; Hart, L.S.; Nakazawa, M.S.; Belcastro, L.T.; Martinez, D.; Li, Y.; Carpenter, E.L.; Attiyeh, E.F.; Diskin, S.J.; et al. Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. *Clin. Cancer Res.* 2013, 19, 6173–6182. [CrossRef] [PubMed]

194. Gelbert, L.M.; Cai, S.; Lin, X.; Sanchez-Martinez, C.; Del Prado, M.; Lallena, M.J.; Torres, R.; Ajamie, R.T.; Wishart, G.N.; Flack, R.S.; et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219: In-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. *Investig. New Drugs* 2014, 32, 825–837. [CrossRef] [PubMed]

195. Bryant, K.L.; Mancias, J.D.; Kimmelman, A.C.; Der, C.J. KRAS: Feeding pancreatic cancer proliferation. *Trends Biochem. Sci.* 2014, 39, 91–100. [CrossRef] [PubMed]
200. Sousa, C.M.; Kimmelman, A.C. The complex landscape of pancreatic cancer metabolism. *Carcinogenesis* 2014, 35, 1441–1450. [CrossRef] [PubMed]

201. Franco, J.; Balaji, U.; Freinkman, E.; Witkiewicz, A.K.; Knudsen, E.S. Metabolic re-programming of pancreatic cancer mediated by CDK4/6 inhibition elicits unique vulnerabilities. *Cell Rep.* 2016, 14, 979–990. [CrossRef] [PubMed]

202. Sabharwal, S.S.; Schumacker, P.T. Mitochondrial ROS in cancer: Initiators, amplifiers or an Achilles’ heel? *Nat. Rev. Cancer* 2014, 14, 709–721. [CrossRef] [PubMed]

203. Franco, J.; Witkiewicz, A.K.; Knudsen, E.S. CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer. *Oncotarget* 2014, 5, 6512–6525. [CrossRef] [PubMed]

204. Retzer-Lidl, M.; Schmid, R.M.; Schneider, G. Inhibition of CDK4 impairs proliferation of pancreatic cancer cells and sensitizes towards TRAIL-induced apoptosis via downregulation of survivin. *Int. J. Cancer* 2007, 121, 66–75. [CrossRef] [PubMed]

205. Roberts, P.J.; Bisi, J.E.; Strum, J.C.; Combest, A.J.; Darr, D.B.; Usary, J.E.; Zamboni, W.C.; Wong, K.K.; Perou, C.M.; Sharpless, N.E. Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer Therapy. *J. Natl. Cancer Inst.* 2012, 104, 476–487. [CrossRef] [PubMed]

206. Dean, J.L.; McClendon, A.K.; Knudsen, E.S. Modification of the DNA damage response by therapeutic CDK4/6 inhibition. *Cancer Cell* 2012, 287, 29075–29087. [CrossRef] [PubMed]

207. Subramaniam, D.; Periyasamy, G.; Ponnurangam, S.; Chakrabarti, D.; Sugumar, A.; Padigaru, M.; Weir, S.J.; Balakrishnan, A.; Sharma, S.; Anant, S. CDK-4 inhibitor P276 sensitizes pancreatic cancer cells to gemcitabine-induced apoptosis. *Mol. Cancer Ther.* 2012, 369, 304–315. [CrossRef] [PubMed]

208. Wei, R.; Kong, L.; Xiao, Y.; Yuan, H.; Song, Y.; Wang, J.; Yu, H.; Mao, S.; Xu, W. CDK8 regulates the angiogenesis of pancreatic cancer cells in part via the CDK8-β-catenin-KLF2 signal axis. *Exp. Cell Res.* 2018, 369, 304–315. [CrossRef] [PubMed]

209. Cros, J.; Raffenne, J.; Couvelard, A.; Pote, N. Tumor Heterogeneity in Pancreatic Adenocarcinoma. *Pathobiology* 2018, 85, 64–71. [CrossRef] [PubMed]

210. Veenstra, V.L.; Garcia-Garijo, A.; van Laarhoven, H.W.; Bijlsma, M.F. Extracellular Influences: Molecular Subclasses and the Microenvironment in Pancreatic Cancer. *Cancers* 2018, 10, 34. [CrossRef] [PubMed]

211. Parry, D.; Guzi, T.; Shanahan, F.; Davis, N.; Prabhavalkar, D.; Usary, J.E.; Zamboni, W.C.; Wong, K.K.; Perou, C.M.; Sharpless, N.E. Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer Therapy. *J. Natl. Cancer Inst.* 2012, 104, 476–487. [CrossRef] [PubMed]

212. Nemunaitis, J.J.; Small, K.A.; Kirschmeier, P.; Zhang, D.; Zhu, Y.; Jou, Y.M.; Statkevich, P.; Yao, S.L.; Bannerji, R. A first-in-human, phase 1 dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies. *J. Transl. Med.* 2013, 11, 259. [CrossRef] [PubMed]

213. Ghia, P.; Scarfò, L.; Perez, S.; Pathiraja, K.; Derosier, M.; Small, K.; McCrary Sisk, C.; Patton, N. Efficacy and safety of dinaciclib vs ofatumumab in patients with relapsed/refractory chronic lymphocytic leukemia. *Blood* 2017, 129, 1876–1878. [CrossRef] [PubMed]

214. Feldmann, G.; Mishra, A.; Bish, S.; Karikari, C.; Garrido-Laguna, I.; Rasheed, Z.; Ottenhof, N.A.; Dadon, T.; Alvarez, H.; Hendrich, V.; et al. Cyclin-dependent kinase inhibitor Dinaciclib (SCH72965) inhibits pancreatic cancer growth and progression inmurine xenograft models. *Cancer Biol. Ther.* 2011, 12, 598–609. [CrossRef] [PubMed]

215. Hamad, N.M.; Elconin, J.H.; Karnoub, A.E.; Bai, W.; Rich, J.N.; Abraham, R.T.; Der, C.J.; Counter, C.M. Distinct requirements for Ras oncogenesis in human versus mouse cells. *Genes Dev.* 2002, 16, 2045–2057. [CrossRef] [PubMed]

216. Lim, K.H.; Baines, A.T.; Fiordalisi, J.J.; Shipitsin, M.; Feig, L.A.; Cox, A.D.; Der, C.J.; Counter, C.M. Activation of RaLa is critical for Ras-induced tumorigenesis of human cells. *Cancer Cell* 2005, 7, 533–545. [CrossRef] [PubMed]

217. Lim, K.H.; O’Hayer, K.; Adam, S.J.; Kendall, S.D.; Campbell, P.M.; Der, C.J.; Counter, C.M. Divergent roles for RaLA and RaLB in malignant growth of human pancreatic carcinoma cells. *Curr. Biol.* 2006, 16, 2385–2394. [CrossRef] [PubMed]
218. Chen, R.; Wierda, W.G.; Chubb, S.; Hawtin, R.E.; Fox, J.A.; Keating, M.J.; Gandhi, V.; Plunkett, W. Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. *Blood* 2009, 113, 4637–4645. [CrossRef] [PubMed]

219. Conroy, A.; Stockett, D.E.; Walker, D.; Arkin, M.R.; Hoch, U.; Fox, J.A.; Hawtin, R.E. SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples. *Cancer Chemother. Pharmacol.* 2009, 64, 723–732. [CrossRef] [PubMed]

220. Heath, E.I.; Bible, K.; Martell, R.E.; Adelman, D.C.; Lorusso, P.M. A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors. *Investig. New Drugs* 2008, 26, 59–65. [CrossRef] [PubMed]

221. Tong, W.G.; Chen, R.; Plunkett, W.; Siegel, D.; Sinha, R.; Harvey, R.D.; Badros, A.Z.; Popplewell, L.; Coutre, S.; Fox, J.A.; et al. Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients with Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma. *J. Clin. Oncol.* 2010, 28, 3015–3022. [CrossRef] [PubMed]

222. Senderowicz, A.M. Flavopiridol: The first cyclin-dependent kinase inhibitor in human clinical trials. *Investig. New Drugs* 1999, 17, 313–320. [CrossRef]

223. Cassaday, R.D.; Goy, A.; Advani, S.; Chawla, P.; Nachankar, R.; Gandhi, M.; Gopal, A.K. A phase II, single-arm, open-label, multicenter study to evaluate the efficacy and safety of P276-00, a cyclin-dependent kinase inhibitor, in patients with relapsed or refractory mantle cell lymphoma. *Clin. Lymphoma Myeloma Leuk.* 2015, 15, 392–397. [CrossRef] [PubMed]

224. Kaur, G.; Stetler-Stevenson, M.; Sebers, S.; Worland, P.; Sedlacek, H.; Myers, C.; Czech, J.; Naik, R.; Sausville, E. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. *J. Natl. Cancer Inst.* 1992, 84, 1736–1740. [CrossRef] [PubMed]

225. Joshi, K.S.; Rathos, M.J.; Mahajan, P.; Wagh, V.; Shenoy, S.; Bhatia, D.; Chile, S.; Sivakumar, M.; Maier, A.; Fiebig, H.H.; et al. P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models. *Mol. Cancer Ther.* 2007, 6, 926–934. [CrossRef] [PubMed]

226. Kumar, V.; Guru, S.K.; Jain, S.K.; Joshi, P.; Gandhi, S.G.; Bharate, S.B.; Bhushan, S.; Bharate, S.S.; Vishwakarma, R.A. A chromatography-free isolation of rohitukine from leaves of *Dysoxylum binectariferum*: Evaluation for in vitro cytotoxicity, CDK inhibition and physicochemical properties. *Bioorg. Med. Chem. Lett.* 2016, 26, 3457–3463. [CrossRef] [PubMed]

227. Rathkopf, D.; Dickson, M.A.; Feldman, D.R.; Carvajal, R.D.; Shah, M.A.; Wu, N.; Lefkowitz, R.; Gonen, M.; Can, L.M.; Dials, H.J.; et al. Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumors. *Clin. Cancer Res.* 2009, 15, 7405–7411. [CrossRef] [PubMed]

228. Dickson, M.A.; Shah, M.A.; Rathkopf, D.; Tse, A.; Carvajal, R.D.; Wu, N.; Lefkowitz, R.A.; Gonen, M.; Can, L.M.; Dials, H.J.; et al. A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol. *Cancer Chemother. Pharmacol.* 2010, 66, 1113–1121. [CrossRef] [PubMed]

229. Fornier, M.N.; Rathkopf, D.; Shah, M.; Patil, S.; O’Reilly, E.; Tse, A.N.; Hudis, C.; Lefkowitz, R.; Kelsen, D.P.; Schwartz, G.K. Phase I Dose-Finding Study of Weekly Docetaxel Followed by Flavopiridol for Patients with Advanced Solid Tumors. *Clin. Cancer Res.* 2007, 13. [CrossRef] [PubMed]

230. Luke, J.J.; D’Adamo, D.R.; Dickson, M.A.; Keohan, M.L.; Carvajal, R.D.; Maki, R.G.; de Stanchina, E.; Musi, E.; Singer, S.; Schwartz, G.K. The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: Preclinical investigations and results of a phase I dose-escalation clinical trial. *Clin. Cancer Res.* 2012, 18, 2638–2647. [CrossRef] [PubMed]

231. U.S. National Library of Medicine. Identifier: NCT0047307. Available online: ClinicalTrials.gov (accessed on 20 September 2018).

232. Carvajal, R.D.; Tse, A.; Shah, M.A.; Lefkowitz, R.A.; Gonen, M.; Gilman-Rosen, L.; Kortmansky, J.; Kelsen, D.P.; Schwartz, G.K.; O’Reilly, E.M. A phase II study of flavopiridol (Alvocidib) in combination with docetaxel in refractory, metastatic pancreatic cancer. *Pancreatology* 2009, 9, 404–409. [CrossRef] [PubMed]

233. U.S. National Library of Medicine. Identifier: NCT00331682. Available online: ClinicalTrials.gov (accessed on 20 September 2018).
234. Flynn, J.; Jones, J.; Johnson, A.J.; Andritsos, L.; Maddocks, K.; Jaglowski, S.; Hessler, J.; Grever, M.R.; Im, E.; Zhou, H.; et al. Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia. *Leukemia* **2015**, *29*, 1524–1529. [CrossRef] [PubMed]

235. Mitri, Z.; Karakas, C.; Wei, C.; Briones, B.; Simmons, H.; Ibrahim, N.; Alvaroz, R.; Murray, J.L.; Keyomarsi, K.; Moulder, S. A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer. *Investig. New Drugs* **2015**, *33*, 890–894. [CrossRef] [PubMed]

236. U.S. National Library of Medicine. Identifier: NCT01783171. Available online: ClinicalTrials.gov (accessed on 20 September 2018).

237. Kumar, S.K.; LaPlant, B.; Chng, W.J.; Zonder, J.; Callander, N.; Fonseca, R.; Fruth, B.; Roy, V.; Erlichman, C.; Stewart, A.K.; et al. Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma. *Blood* **2015**, *125*, 443–448. [CrossRef] [PubMed]

238. Mita, M.M.; Joy, A.A.; Mita, A.; Sankhala, K.; Jou, Y.-M.; Zhang, D.; Statkevich, P.; Zhu, Y.; Yao, S.-L.; Small, K.; et al. Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer. *Clin. Breast Cancer* **2014**, *14*, 169–176. [CrossRef] [PubMed]

239. Stephenson, J.J.; Nemunaitis, J.; Martin, J.C.; Jou, Y.-M.; Zhang, D.; Statkevich, P.; Yao, S.-L.; Zhu, Y.; Zhou, H.; et al. Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer. *Lung Cancer* **2014**, *83*, 219–223. [CrossRef] [PubMed]

240. Xu, H.; Yu, S.; Liu, Q.; Yuan, X.; Mani, S.; Pestell, R.G.; Wu, K. Recent advances of highly selective CDK4/6 inhibitors in breast cancer. *J. Hematol. Oncol.* **2017**, *10*, 97. [CrossRef] [PubMed]

241. U.S. National Library of Medicine. Identifier: NCT02981342. Available online: ClinicalTrials.gov (accessed on 20 September 2018).

242. Dickler, M.N.; Tolaney, S.M.; Rugo, H.S.; Cortés, J.; Diéras, V.; Patt, D.; Wildiers, H.; Hudis, C.A.; O’Shaughnessy, J.; Zamaora, E.; et al. MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2 Metastatic Breast Cancer. *Clin. Cancer Res.* **2017**, *23*, 5218–5224. [CrossRef] [PubMed]

243. Sledge, G.W.; Toi, M.; Neven, P.; Sohn, J.; Inoue, K.; Pivot, X.; Burdava, O.; Okera, M.; Masuda, N.; Kaufman, P.A.; et al. MONARCH 2: Abemaciclib in Combination with Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. *J. Clin. Oncol.* **2017**, *35*, 2875–2884. [CrossRef] [PubMed]

244. Goetz, M.P.; Toi, M.; Campone, M.; Sohn, J.; Paluch-Shimon, S.; Huober, J.; Park, I.H.; Trédan, O.; Chen, S.-C.; Manso, L.; et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. *J. Clin. Oncol.* **2017**, *35*, 3638–3646. [CrossRef] [PubMed]

245. Goldman, J.W.; Shi, P.; Reck, M.; Paz-Ares, L.; Koustenis, A.; Hurt, K.C. Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients with Stage IV Non-Small-Cell Lung Cancer with a Detectable KRAS Mutati. *Clin. Lung Cancer* **2016**, *17*, 80–84. [CrossRef] [PubMed]

246. U.S. Food and Drug Administration. Press Announcements—FDA Approves New Treatment for Certain Advanced or Metastatic Breast Cancers. Available online: https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm578071.htm (accessed on 31 July 2018).

247. U.S. National Library of Medicine. Identifier: NCT02897375. Available online: ClinicalTrials.gov (accessed on 20 September 2018).

248. U.S. National Library of Medicine. Identifier: NCT03454035. Available online: ClinicalTrials.gov (accessed on 20 September 2018).

249. U.S. National Library of Medicine. Identifier: NCT03065062. Available online: ClinicalTrials.gov (accessed on 20 September 2018).

250. Ma, C.X.; Gao, F.; Luo, J.; Northfelt, D.W.; Goetz, M.; Forero, A.; Hoog, J.; Naughton, M.; Ademuyiwa, F.; Suresh, R.; et al. NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer. *Clin. Cancer Res.* **2017**, *23*, 4055–4065. [CrossRef] [PubMed]
251. Finn, R.S.; Martin, M.; Rugo, H.S.; Jones, S.; Im, S.-A.; Gelmon, K.; Harbeck, N.; Lipatov, O.N.; Walshe, J.M.; Moulder, S.; et al. Palbociclib and Letrozole in Advanced Breast Cancer. *N. Engl. J. Med.* 2016, 375, 1925–1936. [CrossRef] [PubMed]

252. Turner, N.C.; Ro, J.; André, F.; Loi, S.; Verma, S.; Iwata, H.; Harbeck, N.; Loibl, S.; Huang Bartlett, C.; Zhang, K.; et al. Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer. *N. Engl. J. Med.* 2015, 373, 209–219. [CrossRef] [PubMed]

253. Lu, J. Palbociclib: A first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer. *J. Hematol. Oncol.* 2015, 8, 98. [CrossRef] [PubMed]

254. U.S. National Library of Medicine. Identifier: NCT02703571. Available online: [ClinicalTrials.gov](https://clinicaltrials.gov) (accessed on 20 September 2018).

255. Asiedu, C.; Biggs, J.; Lilly, M.; Kraft, A.S. Inhibition of leukemic cell growth by the protein kinase C activator bryostatin 1 correlates with the dephosphorylation of cyclin-dependent kinase 2. *Cancer Res.* 1995, 55, 3716–3720. [PubMed]

256. Lam, A.P.; Sparano, J.A.; Vinciguerra, V.; Ocean, A.J.; Christos, P.; Hochster, H.; Camacho, F.; Goel, S.; Mani, S.; Kaubisch, A. Phase II study of paclitaxel plus the protein kinase C inhibitor bryostatin-1 in advanced pancreatic carcinoma. *Am. J. Clin. Oncol.* 2010, 33, 121–124. [CrossRef] [PubMed]

257. Aspeslagh, S.; Shailubhai, K.; Bahleda, R.; Gazzah, A.; Varga, A.; Hollebecque, A.; Massard, C.; Spreafico, A.; Reni, M.; Soria, J.-C. Phase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors. *Cancer Chemother. Pharmacol.* 2017, 79, 1257–1265. [CrossRef] [PubMed]

258. Motwani, M.; Delohery, T.M.; Schwartz, G.K.; Patil, S.; O’Reilly, E.; Tse, A.N.; Hudis, C.; Lefkowitz, R.; Kelsen, D.P.; Schwartz, G.K. Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. *Clin. Cancer Res.* 1999, 5, 1876–1883. [CrossRef] [PubMed]

259. Zhang, B. Ofatumumab. *mAbs* 2009, 1, 326–331. [CrossRef] [PubMed]